CA2686439A1 - Compound and device for treating bone and/or cartilage defects - Google Patents
Compound and device for treating bone and/or cartilage defects Download PDFInfo
- Publication number
- CA2686439A1 CA2686439A1 CA002686439A CA2686439A CA2686439A1 CA 2686439 A1 CA2686439 A1 CA 2686439A1 CA 002686439 A CA002686439 A CA 002686439A CA 2686439 A CA2686439 A CA 2686439A CA 2686439 A1 CA2686439 A1 CA 2686439A1
- Authority
- CA
- Canada
- Prior art keywords
- collagen
- growth factor
- bmp
- composition according
- osteo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 86
- 230000007547 defect Effects 0.000 title claims abstract description 39
- 210000000845 cartilage Anatomy 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 163
- 102000008186 Collagen Human genes 0.000 claims abstract description 160
- 108010035532 Collagen Proteins 0.000 claims abstract description 160
- 229920001436 collagen Polymers 0.000 claims abstract description 159
- 239000003102 growth factor Substances 0.000 claims abstract description 106
- 239000000463 material Substances 0.000 claims abstract description 95
- 238000000034 method Methods 0.000 claims abstract description 71
- 230000004069 differentiation Effects 0.000 claims abstract description 60
- 230000002138 osteoinductive effect Effects 0.000 claims abstract description 37
- 230000000694 effects Effects 0.000 claims abstract description 35
- 238000011049 filling Methods 0.000 claims abstract description 34
- 241001465754 Metazoa Species 0.000 claims abstract description 16
- 239000000126 substance Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 241000282414 Homo sapiens Species 0.000 claims description 65
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 63
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 63
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 63
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 238000002156 mixing Methods 0.000 claims description 34
- 239000013543 active substance Substances 0.000 claims description 29
- 230000000278 osteoconductive effect Effects 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 239000011148 porous material Substances 0.000 claims description 22
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 21
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 20
- 239000001506 calcium phosphate Substances 0.000 claims description 20
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 20
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 20
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 18
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 18
- 102000012422 Collagen Type I Human genes 0.000 claims description 17
- 108010022452 Collagen Type I Proteins 0.000 claims description 17
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 17
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 17
- 229910052751 metal Inorganic materials 0.000 claims description 15
- 239000002184 metal Substances 0.000 claims description 15
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 14
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 14
- 229910010293 ceramic material Inorganic materials 0.000 claims description 14
- 239000007943 implant Substances 0.000 claims description 14
- 150000002739 metals Chemical class 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 14
- 241000283690 Bos taurus Species 0.000 claims description 13
- 239000000654 additive Substances 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 13
- 238000001356 surgical procedure Methods 0.000 claims description 13
- 241000283073 Equus caballus Species 0.000 claims description 12
- 230000034127 bone morphogenesis Effects 0.000 claims description 12
- 230000000996 additive effect Effects 0.000 claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 8
- 239000000919 ceramic Substances 0.000 claims description 8
- 230000011164 ossification Effects 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 7
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 230000022159 cartilage development Effects 0.000 claims description 7
- 239000000824 cytostatic agent Substances 0.000 claims description 7
- 238000002513 implantation Methods 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 230000035800 maturation Effects 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 5
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 4
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 102000013275 Somatomedins Human genes 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 230000001085 cytostatic effect Effects 0.000 claims description 4
- 230000013595 glycosylation Effects 0.000 claims description 4
- 102000045896 human BMP2 Human genes 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 230000000979 retarding effect Effects 0.000 claims description 4
- 239000008174 sterile solution Substances 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 102000004506 Blood Proteins Human genes 0.000 claims description 3
- 108010017384 Blood Proteins Proteins 0.000 claims description 3
- 102000002068 Glycopeptides Human genes 0.000 claims description 3
- 108010015899 Glycopeptides Proteins 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- 235000019833 protease Nutrition 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 2
- 244000063299 Bacillus subtilis Species 0.000 claims description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
- 102000001187 Collagen Type III Human genes 0.000 claims description 2
- 108010069502 Collagen Type III Proteins 0.000 claims description 2
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 claims description 2
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical class [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000002051 biphasic effect Effects 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- 235000019419 proteases Nutrition 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229940014800 succinic anhydride Drugs 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 241000187747 Streptomyces Species 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000011159 matrix material Substances 0.000 description 11
- 108010030102 COLLOSS E Proteins 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000008929 regeneration Effects 0.000 description 9
- 238000011069 regeneration method Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 229940096422 collagen type i Drugs 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 102000007000 Tenascin Human genes 0.000 description 6
- 108010008125 Tenascin Proteins 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102000005593 Endopeptidases Human genes 0.000 description 5
- 108010059378 Endopeptidases Proteins 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 102000006395 Globulins Human genes 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 102000007327 Protamines Human genes 0.000 description 4
- 108010007568 Protamines Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940048914 protamine Drugs 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 210000002805 bone matrix Anatomy 0.000 description 3
- 239000000316 bone substitute Substances 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000002188 osteogenic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 101150061927 BMP2 gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 102000046949 human MSC Human genes 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 101000984012 Gallus gallus Cadherin-1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- -1 TGF-(31 Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241001447056 Uristes Species 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000002977 biomimetic material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000004068 calcium phosphate ceramic Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000003848 cartilage regeneration Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000002820 chemotaxin Substances 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro- stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil.
Description
Compound and device for treating bone and/or cartilage defects Related applications The present application is related to German patent application number 10 2007 276.6 filed in the German Patent Office on March 8, 2007, U.S. provisional application serial number 60/993,146, filed September 10, 2007 in the U.S. Patent and Trademark Office, and PCT application PCT/EP2008/001604, the contents of each of which is hereby incorporated herein in its entirety.
Technical Field The present invention provides compositions, devices, and method of manufacturing thereof, and methods for treating bone and/or cartilage defects.
Back ound Natural bone is made up of a combination of inorganic elements, organic elements, and water. Inorganic elements, for example hydroxyapatite, make up approximately 70% of natural bone. Organic elements such as collagen type I make up approximately 20% of natural bone, and water makes up approximately 10%. Bone-forming cells, for example osteoblasts, produce and secrete or bind the organic elements. Further, non-collagen proteins, in particular osteocalcin, osteonectin, osteopontin, cytokine, growth inducing factor, proteoglycan and fat are present in natural bone.
Natural bone is constantly being degraded and regenerated, i.e. re-modelled.
Osteogenesis, i.e., bone regeneration, originates from the bone itself, as observed for example during healing of bone fractures. Thus, natural bone has the capability to generate new functional bone.
In many cases, however, regeneration of natural bone is restricted. This may be caused by, for example, the extent of a bone defect or by different functional disorders, for example metabolic disturbances. Treatment of bone defects remains an important field, for example in orthopedics, repair to jaws, teeth and hands, surgery in connection with accidents, and facial surgery.
Bone defects have different origins, caused for example by cysts, atrophies, or tumors.
Complicated comminute fractures, congenital deformities and loosening of implants also cause bone defects. There is increasing focus on the reconstruction of bone defects using suitable materials.
Bone graft substitute products on the market include InFuse manufactured by Medtronic Sofamor Danek (Minneapolis, MN), and OP-1 Putty manufactured by Stryker Corporation (Kalamazoo, MI). These products are sold as kits that separately contain a bovine collagen scaffold and human recombinant Bone Morphogenic Protein ("rhBMP") in a vial.
InFuse uses rhBMP-2 which prior to implantation is soaked onto a sponge. OP-1 Putty is provided as two components: a vial containing one gram dry powder of bovine collagen, OP-10, rhBMP-7, and another vial containing a putty additive of carboxymethylcellulose dry powder. Both components must be combined with saline to produce the implant. According to the OP-1 Putty package insert, 96% of patients treated with OP-1 Putty develop an immune response to the product.
With each of these products, the rhBMP component is applied to the scaffold is performed during the surgical procedure. Applying the rhBMP solution to the surface of the scaffold potentially results in a heterogeneous distribution of the rhBMP, i.e., certain areas of the scaffold will have a higher concentration of rhBMP than other areas of the scaffold. Further, as the surgeon is required to assemble the product in the operating room, there exists a risk of infection and inconsistent dosage from procedure to procedure.
There is a need for sterile homogeneous devices and compositions with high osteo-inductive or chondro-inductive activities and methods for treating bone and/or cartilage defects.
Summary The invention in one embodiment provides a composition for treating bone and/or cartilage defects, having at least one collagen, preferably of animal origin, and preferably containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect; and at least one filling material, in which the composition is in the form of a lyophil. In general, the at least one differentiation or growth factor is a protein or peptide, preferably a glycoprotein or glycopeptide, preferably a cytokine, for example the differentiation or growth factor is a human differentiation or growth factor. In a related embodiment, the differentiation or growth factor is recombinantly produced. In general, the differentiation or growth factor comprises at least one member of the TGF (Transforming Growth Factor) family.
For example, the differentiation or growth factor comprises at least one member of the group of BMP (Bone Morphogenetic Proteins), preferably BMP-2 and/or BMP-7.
Alternatively, the differentiation or growth factor is a TGF-(3 (Transforming Growth Factor beta) or is a VEGF (Vascular Endothelial Growth Factor).
The composition in certain embodiments includes, the differentiation or growth factor in relation to the amount of collagen, osteo-inductive or chondro-inductive activity, as a share of about 0.005 to about 5 percent by weight, preferably from about 0.01 to about 4 percent by weight. For example, the differentiation or growth factor comprises a share of about 0.05 to about 2 percent by weight, preferably from about 0.1 to about 5 percent by weight, preferably from about 0.5 to about 3 percent by weight. The composition further includes at least one scaffold material, preferably a scaffold material having osteo-conductive properties. For example, the scaffold is collagen, preferably type I collagen. Alternatively, or in addition the scaffold material is at least one selected from the group of ceramics, biologically compatible metals and biologically compatible polymers. Alternatively, or in addition the scaffold material is an extract of native bone, preferably a demineralized bone matrix (DBM).
Alternatively the composition includes a growth factor having chondro-inductive properties, such as TFG-j3.
In certain embodiments, the composition further includes at least one additional active substance, preferably at least one cytostatic and/or at least one antibiotic.
For example the composition includes further at least one component selected from the group of: at least one recruiting factor, at least one adhesion factor, at least one growth factor and at least one maturation factor for osteogenesis or chondrogenesis.
In general, the collagen is of mammalian origin, preferably of human, bovine, porcine or equine origin. In general, the composition further includes pores, preferably interconnecting pores, preferably pores having a diameter in the range of about 100 m to about 300 m, and the composition has a sponge-like consistency. The pores can arise from a lyophililization process, from a tunneling of ice crystal across a thermal gradient, or from a granulation process. In general, the composition is at least partially bioresorbable, preferably completely bio-resorbable.
The composition is produced in the form of a paste a gel or a lyophil.
Accordingly, the composition has a substantially form-stable body.
In another embodiment, the invention provides a composition for treating bone and/or cartilage defects having at least one recombinant collagen, preferably of human origin, and preferably containing at least one substance having an osteo-inductive or chondro-inductive activity, such that the osteo-inductive or chondro-inductive activity is at least one recombinant bone morphogenesis protein (BMP). In general, the BIvIl' is of mammalian origin, preferably of equine, porcine or bovine origin. For example, the BMP is of human origin.
Similarly, the BMP
has an amino acid sequence at least about 70% identical to a BMP of human origin. The BMP in certain embodiments is recombinantly produced in a yeast or in a bacterium.
For example, the BMP is recombinantly produced in bacterium Escherichia coli, or in Bacillus subtilis, or Streptornyces spp. Alternatively, the BMP is recombinantly produced in a cell capable of protein glycosylation. For example, the BMP is produced in a cell selected from the group consisting of mammalian, bird, yeast, and insect.
In certain embodiments, the BMP, in relation to the amount of collagen comprises a proportion of about 0.005 to about 5 weight percent, preferably from 0.01 to 4 weight percent.
The BMP comprises a proportion of about 0.05 to about 20 weight percent, preferably from about 0.1 to about 5 weight percent, preferably from 0.5 to 3 weight percent.
In certain embodiments, the further additionally includes at least one scaffold material having osteo-conductive properties. For example, the scaffold material includes collagen, preferably type I collagen, preferably human type I collagen. Alternatively the collagen is type III. The scaffold material comprises at least one substance selected from the group of tricalcium phosphate, ceramic materials, biologically compatible metals, and biologically compatible polymers. For example, the scaffold material is tricalcium phosphate or a biphasic material comprising tricalcium phosphate. These ceramics are made at different sintering temperatures as is well known to one of ordinary skill in the ceramics art. The composition can further include at least one additional active substance, preferably at least one cytostatic and/or at least one antibiotic. For example, the composition further includes at least one additional component having an activity selected from the group of at least one recruiting factor, at least one adhesion factor, at least one growth factor and at least one maturation factor for osteogenesis or chondrogenesis. In general the human collagen is recombinantly produced.
The composition in general has a porous form, with pores, preferably interconnecting pores, preferably with diameters having a size in the range of about 100 m to about 300 m such that the composition has a spongy consistency. The pores arise from the lyophilization or granulation process, as the composition is "non-woven" material.
The composition in general is substantially bioresorbable or is essentially completely bioresorbable. The composition is provided as a lyophil, a gel, or a paste, and is a substantially form-stable body.
Thus, an embodiment of the invention provides a composition for treating bone and/or cartilage defects comprising an aseptically prepared admixture of a recombinant human collagen and a recombinant human bone morphogenesis protein (BNIl') such that the collagen and the BMP are sterile and are aseptically mixed and co-lyophilized or co-granulated.
For example, the BMP has an amino acid sequence that is at least about 70%, about 80%, about 85%, about 90%, or at least about 95% identical to an amino acid sequence of a BMP of human origin. The BMP
in certain embodiments is produced in a bacterium, for example, the BMP is produced in E. coli.
Alternatively, the BMP is recombinantly produced in a cell capable of protein glycosylation. For example, the BMP is produced in a cell selected from the group consisting of a mammalian, bird, yeast, and insect cell. The BMP, in relation to the amount of collagen comprises a proportion of about 0.005 to about 5 weight percent, preferably from 0.01 to 4 weight percent.
For example, the BMP comprises a proportion of about 0.05 to about 2 weight percent, preferably from about 0.1 to about 5 weight percent, preferably from about 0.5 to about 3 weight percent.
The invention in a further embodiment provides a method for manufacturing any of the above compositions, the method including: mixing components comprising at least one collagen, preferably of animal origin and preferably having at least one osteo-inductive or chondro-inductive activity, with at least one differentiation or growth factor having osteo-stimulative and/or chondro-stimulative activity, and co-lyophilizing the components to obtain an at least partly form-stable, spongy body. In an embodiment in which collagen is of non-human origin, the method further includes prior to mixing, contacting the collagen with a peptidase or protease, preferably trypsin. The method further involves, prior to mixing, concentrating the differentiation or growth factor, preferably in at least one separation step.
A related embodiment of the method further includes prior to mixing, adding at least one scaffold material, such that the scaffold material has osteo-conductive properties and is selected from the group of ceramic materials, biologically compatible metals, biologically compatible polymers and extracts of native bone, preferably DBM, and mixing, preferably coating, with collagen;
and mixing with at least one collagen, preferably of animal origin with an osteo-inductive or a chondro-inductive, active substance and/or at least one additive of at least one differentiation or growth factor with osteo-stimulative and/or chondro-stimulative effect; and colyophilizing the components to obtain an at least partly form stable, spongy body. The method according to the above is performed under aseptic conditions.
Also provided herein is use of at least one differentiation and/or growth factor with osteo-stimulative and/or chondro-stimulative effect, the use comprising mixing aseptically an aseptic or a sterile solution of the growth factor with an aseptic or a sterile solution of at least one collagen, preferably of animal origin and preferably having at least one osteo-inductive or Qhondro-inductive, active substance; and, co-lyophilizing aseptically the resulting mixture in a container for single use as an implant in surgery.
Further provided herein is use of at least one human bone morphogenesis protein (BMP) for treating a bone and/or cartilage defect during a surgical procedure, the use comprising adding the BMP to at least one human collagen and at least one scaffold material to obtain an admixture, and providing the admixture as an aseptic device for treating a bone and/or cartilage defect during a surgical procedure. The above uses are in the form of a device, which is provided as a surgery-ready unit dose. The composition is a lyophil, a gel or a paste.
Technical Field The present invention provides compositions, devices, and method of manufacturing thereof, and methods for treating bone and/or cartilage defects.
Back ound Natural bone is made up of a combination of inorganic elements, organic elements, and water. Inorganic elements, for example hydroxyapatite, make up approximately 70% of natural bone. Organic elements such as collagen type I make up approximately 20% of natural bone, and water makes up approximately 10%. Bone-forming cells, for example osteoblasts, produce and secrete or bind the organic elements. Further, non-collagen proteins, in particular osteocalcin, osteonectin, osteopontin, cytokine, growth inducing factor, proteoglycan and fat are present in natural bone.
Natural bone is constantly being degraded and regenerated, i.e. re-modelled.
Osteogenesis, i.e., bone regeneration, originates from the bone itself, as observed for example during healing of bone fractures. Thus, natural bone has the capability to generate new functional bone.
In many cases, however, regeneration of natural bone is restricted. This may be caused by, for example, the extent of a bone defect or by different functional disorders, for example metabolic disturbances. Treatment of bone defects remains an important field, for example in orthopedics, repair to jaws, teeth and hands, surgery in connection with accidents, and facial surgery.
Bone defects have different origins, caused for example by cysts, atrophies, or tumors.
Complicated comminute fractures, congenital deformities and loosening of implants also cause bone defects. There is increasing focus on the reconstruction of bone defects using suitable materials.
Bone graft substitute products on the market include InFuse manufactured by Medtronic Sofamor Danek (Minneapolis, MN), and OP-1 Putty manufactured by Stryker Corporation (Kalamazoo, MI). These products are sold as kits that separately contain a bovine collagen scaffold and human recombinant Bone Morphogenic Protein ("rhBMP") in a vial.
InFuse uses rhBMP-2 which prior to implantation is soaked onto a sponge. OP-1 Putty is provided as two components: a vial containing one gram dry powder of bovine collagen, OP-10, rhBMP-7, and another vial containing a putty additive of carboxymethylcellulose dry powder. Both components must be combined with saline to produce the implant. According to the OP-1 Putty package insert, 96% of patients treated with OP-1 Putty develop an immune response to the product.
With each of these products, the rhBMP component is applied to the scaffold is performed during the surgical procedure. Applying the rhBMP solution to the surface of the scaffold potentially results in a heterogeneous distribution of the rhBMP, i.e., certain areas of the scaffold will have a higher concentration of rhBMP than other areas of the scaffold. Further, as the surgeon is required to assemble the product in the operating room, there exists a risk of infection and inconsistent dosage from procedure to procedure.
There is a need for sterile homogeneous devices and compositions with high osteo-inductive or chondro-inductive activities and methods for treating bone and/or cartilage defects.
Summary The invention in one embodiment provides a composition for treating bone and/or cartilage defects, having at least one collagen, preferably of animal origin, and preferably containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect; and at least one filling material, in which the composition is in the form of a lyophil. In general, the at least one differentiation or growth factor is a protein or peptide, preferably a glycoprotein or glycopeptide, preferably a cytokine, for example the differentiation or growth factor is a human differentiation or growth factor. In a related embodiment, the differentiation or growth factor is recombinantly produced. In general, the differentiation or growth factor comprises at least one member of the TGF (Transforming Growth Factor) family.
For example, the differentiation or growth factor comprises at least one member of the group of BMP (Bone Morphogenetic Proteins), preferably BMP-2 and/or BMP-7.
Alternatively, the differentiation or growth factor is a TGF-(3 (Transforming Growth Factor beta) or is a VEGF (Vascular Endothelial Growth Factor).
The composition in certain embodiments includes, the differentiation or growth factor in relation to the amount of collagen, osteo-inductive or chondro-inductive activity, as a share of about 0.005 to about 5 percent by weight, preferably from about 0.01 to about 4 percent by weight. For example, the differentiation or growth factor comprises a share of about 0.05 to about 2 percent by weight, preferably from about 0.1 to about 5 percent by weight, preferably from about 0.5 to about 3 percent by weight. The composition further includes at least one scaffold material, preferably a scaffold material having osteo-conductive properties. For example, the scaffold is collagen, preferably type I collagen. Alternatively, or in addition the scaffold material is at least one selected from the group of ceramics, biologically compatible metals and biologically compatible polymers. Alternatively, or in addition the scaffold material is an extract of native bone, preferably a demineralized bone matrix (DBM).
Alternatively the composition includes a growth factor having chondro-inductive properties, such as TFG-j3.
In certain embodiments, the composition further includes at least one additional active substance, preferably at least one cytostatic and/or at least one antibiotic.
For example the composition includes further at least one component selected from the group of: at least one recruiting factor, at least one adhesion factor, at least one growth factor and at least one maturation factor for osteogenesis or chondrogenesis.
In general, the collagen is of mammalian origin, preferably of human, bovine, porcine or equine origin. In general, the composition further includes pores, preferably interconnecting pores, preferably pores having a diameter in the range of about 100 m to about 300 m, and the composition has a sponge-like consistency. The pores can arise from a lyophililization process, from a tunneling of ice crystal across a thermal gradient, or from a granulation process. In general, the composition is at least partially bioresorbable, preferably completely bio-resorbable.
The composition is produced in the form of a paste a gel or a lyophil.
Accordingly, the composition has a substantially form-stable body.
In another embodiment, the invention provides a composition for treating bone and/or cartilage defects having at least one recombinant collagen, preferably of human origin, and preferably containing at least one substance having an osteo-inductive or chondro-inductive activity, such that the osteo-inductive or chondro-inductive activity is at least one recombinant bone morphogenesis protein (BMP). In general, the BIvIl' is of mammalian origin, preferably of equine, porcine or bovine origin. For example, the BMP is of human origin.
Similarly, the BMP
has an amino acid sequence at least about 70% identical to a BMP of human origin. The BMP in certain embodiments is recombinantly produced in a yeast or in a bacterium.
For example, the BMP is recombinantly produced in bacterium Escherichia coli, or in Bacillus subtilis, or Streptornyces spp. Alternatively, the BMP is recombinantly produced in a cell capable of protein glycosylation. For example, the BMP is produced in a cell selected from the group consisting of mammalian, bird, yeast, and insect.
In certain embodiments, the BMP, in relation to the amount of collagen comprises a proportion of about 0.005 to about 5 weight percent, preferably from 0.01 to 4 weight percent.
The BMP comprises a proportion of about 0.05 to about 20 weight percent, preferably from about 0.1 to about 5 weight percent, preferably from 0.5 to 3 weight percent.
In certain embodiments, the further additionally includes at least one scaffold material having osteo-conductive properties. For example, the scaffold material includes collagen, preferably type I collagen, preferably human type I collagen. Alternatively the collagen is type III. The scaffold material comprises at least one substance selected from the group of tricalcium phosphate, ceramic materials, biologically compatible metals, and biologically compatible polymers. For example, the scaffold material is tricalcium phosphate or a biphasic material comprising tricalcium phosphate. These ceramics are made at different sintering temperatures as is well known to one of ordinary skill in the ceramics art. The composition can further include at least one additional active substance, preferably at least one cytostatic and/or at least one antibiotic. For example, the composition further includes at least one additional component having an activity selected from the group of at least one recruiting factor, at least one adhesion factor, at least one growth factor and at least one maturation factor for osteogenesis or chondrogenesis. In general the human collagen is recombinantly produced.
The composition in general has a porous form, with pores, preferably interconnecting pores, preferably with diameters having a size in the range of about 100 m to about 300 m such that the composition has a spongy consistency. The pores arise from the lyophilization or granulation process, as the composition is "non-woven" material.
The composition in general is substantially bioresorbable or is essentially completely bioresorbable. The composition is provided as a lyophil, a gel, or a paste, and is a substantially form-stable body.
Thus, an embodiment of the invention provides a composition for treating bone and/or cartilage defects comprising an aseptically prepared admixture of a recombinant human collagen and a recombinant human bone morphogenesis protein (BNIl') such that the collagen and the BMP are sterile and are aseptically mixed and co-lyophilized or co-granulated.
For example, the BMP has an amino acid sequence that is at least about 70%, about 80%, about 85%, about 90%, or at least about 95% identical to an amino acid sequence of a BMP of human origin. The BMP
in certain embodiments is produced in a bacterium, for example, the BMP is produced in E. coli.
Alternatively, the BMP is recombinantly produced in a cell capable of protein glycosylation. For example, the BMP is produced in a cell selected from the group consisting of a mammalian, bird, yeast, and insect cell. The BMP, in relation to the amount of collagen comprises a proportion of about 0.005 to about 5 weight percent, preferably from 0.01 to 4 weight percent.
For example, the BMP comprises a proportion of about 0.05 to about 2 weight percent, preferably from about 0.1 to about 5 weight percent, preferably from about 0.5 to about 3 weight percent.
The invention in a further embodiment provides a method for manufacturing any of the above compositions, the method including: mixing components comprising at least one collagen, preferably of animal origin and preferably having at least one osteo-inductive or chondro-inductive activity, with at least one differentiation or growth factor having osteo-stimulative and/or chondro-stimulative activity, and co-lyophilizing the components to obtain an at least partly form-stable, spongy body. In an embodiment in which collagen is of non-human origin, the method further includes prior to mixing, contacting the collagen with a peptidase or protease, preferably trypsin. The method further involves, prior to mixing, concentrating the differentiation or growth factor, preferably in at least one separation step.
A related embodiment of the method further includes prior to mixing, adding at least one scaffold material, such that the scaffold material has osteo-conductive properties and is selected from the group of ceramic materials, biologically compatible metals, biologically compatible polymers and extracts of native bone, preferably DBM, and mixing, preferably coating, with collagen;
and mixing with at least one collagen, preferably of animal origin with an osteo-inductive or a chondro-inductive, active substance and/or at least one additive of at least one differentiation or growth factor with osteo-stimulative and/or chondro-stimulative effect; and colyophilizing the components to obtain an at least partly form stable, spongy body. The method according to the above is performed under aseptic conditions.
Also provided herein is use of at least one differentiation and/or growth factor with osteo-stimulative and/or chondro-stimulative effect, the use comprising mixing aseptically an aseptic or a sterile solution of the growth factor with an aseptic or a sterile solution of at least one collagen, preferably of animal origin and preferably having at least one osteo-inductive or Qhondro-inductive, active substance; and, co-lyophilizing aseptically the resulting mixture in a container for single use as an implant in surgery.
Further provided herein is use of at least one human bone morphogenesis protein (BMP) for treating a bone and/or cartilage defect during a surgical procedure, the use comprising adding the BMP to at least one human collagen and at least one scaffold material to obtain an admixture, and providing the admixture as an aseptic device for treating a bone and/or cartilage defect during a surgical procedure. The above uses are in the form of a device, which is provided as a surgery-ready unit dose. The composition is a lyophil, a gel or a paste.
Another embodiment herein provides a method for formulating a composition for treating bone and cartilage defects, the method comprising: mixing aseptically a solution of a recombinant human collagen with a solution of an amino acid sequence of a recombinant human bone morphogenesis protein; and granulating or lyophilizing aseptically the admixture to a gel, paste, or a lyophil having an at least partly form-stable shape and a spongy consistency. In general, the solution of the collagen and the solution of the bone morphogenesis protein have reduced microbial content includes, or are sterile. Thus the method includes, prior to the mixing, concentrating the collagen, preferably in at least one separation step, and the collagen is treated with acid or filter sterilized prior to or after concentrating. Further the method can include prior to mixing, providing at least one scaffold material selected from the group of ceramic materials, biologically compatible metals, biologically compatible polymers and extracts of native bone, preferably DBM; mixing or preferably coating the scaffold material with the collagen; and colyophilizing or co-granulating the admixture to obtain an at least partly form-stable, spongy body. Prior to mixing, the collagen is sterilized by filter sterilizing or acidifying, the scaffold material is irradiated, and mixing is performed under aseptic conditions.
Yet another embodiment of the invention herein provides a kit for treating a bone and/or cartilage defect during a surgical procedure, the kit having an aseptically prepared admixture in the fonn of a lyophil, a gel or a paste, the admixture comprising a recombinant human bone morphogenesis protein (BMP) and a recombinant human collagen, in a container.
The kit is for example, such that the admixture is present in a surgery ready unit dose. In a related embodiment the kit further has instructions for direct use of the aseptic admixture as an implant without additional manipulation.
An embodiment of the invention herein provides an aseptic device for surgical implantation for treating bone and/or cartilage defects which has an admixture of a recombinantly produced hurrian differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect and at least one scaffold material, such that the factor is at least about 70% identical in amino acid sequence to a human growth factor, and the device is provided as a single component for surgical implantation. In one embodimeint, the growth factor is glycosylated. Alternatively, the growth factor is recombinantly produced in a cell of a yeast, a mammal or a bird. For example, the growth factor is non-glycosylated, the growth factor is recombinantly produced in a bacterium, for example, in E. coli.
In general the growth factor in the device is a meinber of the TGF
(Transforming Growth Factor) family. For example, the growth factor is at least one of Bone Morphogenetic Proteins (BMP) comprising BMP-2, BMP-7, BMP-9, BMP-16; Vascular Endothelial Growth Factor (VEGF); Transforming Growth Factor (3 (TGF(3), Platelet Derived Growth Factor (PDGF), Insulin-like Growth Factor (IGF) and p15. In one particular embodiment, the growth factor is a human BMP-2 or a human BMP-7 that is recombinantly produced and is nature identical. In general, the embodiments of the device that include collagen, the ratio of the differentiation or growth factor in relation to the amount of collagen comprises a share of about 0.005 to about 5 percent by weight, preferably from about 0.01 to about 4 percent by weight.
For example, the growth factor comprises a share of about 0.05 to about 2 percent by weight, preferably from about 0.1 to about 5 percent by weight, preferably from about 0.5 to about 3 percent by weight.
The device in related embodiments includes at least one scaffold material, preferably a scaffold material having an osteo-conductive activity. For example, the scaffold is collagen having an amino acid sequence substantially identical to a human collagen.
Further, the collagen is recoinbinantly produced. Alternatively or in addiction, the scaffold material is at least one selected from the group of ceramics, biologically compatible metals and biologically compatible polymers. The device can further include at least one additional active substance selected from the group of at least one cytostatic agent and/or at least one antibiotic.
Alternatively, the device can further include at least one component selected from the group of:
a recruiting factor, an adhesion factor, a growth factor and a maturation factor for osteogenesis or chondrogenesis. The device in general is a co-lyophil or a co-granulate and is a spongy form-stable body that comprises pores. The pores have a diameter in the range of about 100 m to about 300 m, and such that the admixture has a consistency and stable form of a surgical sponge. The device admixture in related embodiments is at least partially bio-resorbable, and is preferably completely bio-resorbable. The admixture is generally aseptically prepared from aseptic or sterile components. The device in various embodiments is proyided in a closed container. In a particular embodiment, the admixture is aseptically lyophilized in the container.
For example, the container is aseptically covered with a material capable of unidirectional passage of solvent molecules during lyophililization.
In general the scaffold material includes human recombinant collagen. For example, the collagen is selected from at least one of a type I collagen and a type III
collagen. Alternatively or in addition, the scaffold material comprises a mineral. For example, the mineral is selected from the group consisting of: tricalcium phosphate, ceramic materials, biologically compatible metals, and biologically compatible polymers. In certain embodiments, the device includes collagen that is cross-linked using a commonly known reagent for cross-linking proteins. For example, the collagen is covalently internally cross-linked to itself, or the collagen is covalently linked to the growth factor. Thus the collagen is covalently cross-linked in solution to the growth factor to obtain a matrix, and then the matrix is lyophilized aseptically and used as an implant in a subject for treatment of a bone and/or a cartilage defect.
Accordingly, following implant into the subject, the matrix is subsequently metabolized releasing slowly the covalently bound growth factor such as BMP-2 or BMP-7, compared to release of an otherwise identically constituted and non-covalently bound matrix releasing growth factor in a burst at an early time point following implant into the subject.
In certain embodiments of the device, the covalently cross linked collagen is obtained by contacting the collagen and osteo- and/or chondro-stimulating factors with a bidentate, low molecular cross-linking reagent selected from the group of commonly used in protein and peptide chemistry reagents: 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), succinic anhydride, a di-isocyanates, an activated and properly protected amino acids, a double activated polyethylene-glycol, and an activated carbon hydrate to obtain quantitative binding of the reagent to the collagen.
Accordingly, the device, following quantitative binding of the reagent to collagen is further prepared by the steps of: removing excess reagent by dialyzing, to obtain a modified collagen that retains protein features having a biological activity selected from the group of osteo-inductive, chondro-inductive, osteo-conductive and chrondo-conductive; mixing the modified collagen with the factor/s for a time appropriate for cross-linking; and lyophilyzing, such that the steps are perforined aseptically. The device in embodiments above includes materials that are aseptic, such that the device has a reduced microbial content.
In yet another embodiment, the device contains at least one additional component that retards release of the growth factor from the scaffold, for example from the collagen. The additional component retards release of the growth factor by non-covalent affinity, for example, the additional component is a plasma protein such as fibrin or a globulin. The additional component is in related embodiments of human origin, and/or is recombinantly produced.
Detailed Description A problem in treatment of bone and cartilage defects is that certain synthetic materials currently used to repair bone defects are poorly absorbed or are non-bioresorbable. These include ceramic materials, for example porous calcium phosphate ceramics. Such materials have useful osteo-conductive properties, i.e., the materials are able to provide regenerating bone tissue with a structure creating matrix (guide structure) with sufficient mechanical stability.
Bone generating cells bind to materials with osteo-conductive properties, and then precipitate a bone matrix around or inside this material. Ceramic materials, however, remain in an unchanged state in the body, and are consequently overgrown and penetrated by the newly generated bone.
Yet another embodiment of the invention herein provides a kit for treating a bone and/or cartilage defect during a surgical procedure, the kit having an aseptically prepared admixture in the fonn of a lyophil, a gel or a paste, the admixture comprising a recombinant human bone morphogenesis protein (BMP) and a recombinant human collagen, in a container.
The kit is for example, such that the admixture is present in a surgery ready unit dose. In a related embodiment the kit further has instructions for direct use of the aseptic admixture as an implant without additional manipulation.
An embodiment of the invention herein provides an aseptic device for surgical implantation for treating bone and/or cartilage defects which has an admixture of a recombinantly produced hurrian differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect and at least one scaffold material, such that the factor is at least about 70% identical in amino acid sequence to a human growth factor, and the device is provided as a single component for surgical implantation. In one embodimeint, the growth factor is glycosylated. Alternatively, the growth factor is recombinantly produced in a cell of a yeast, a mammal or a bird. For example, the growth factor is non-glycosylated, the growth factor is recombinantly produced in a bacterium, for example, in E. coli.
In general the growth factor in the device is a meinber of the TGF
(Transforming Growth Factor) family. For example, the growth factor is at least one of Bone Morphogenetic Proteins (BMP) comprising BMP-2, BMP-7, BMP-9, BMP-16; Vascular Endothelial Growth Factor (VEGF); Transforming Growth Factor (3 (TGF(3), Platelet Derived Growth Factor (PDGF), Insulin-like Growth Factor (IGF) and p15. In one particular embodiment, the growth factor is a human BMP-2 or a human BMP-7 that is recombinantly produced and is nature identical. In general, the embodiments of the device that include collagen, the ratio of the differentiation or growth factor in relation to the amount of collagen comprises a share of about 0.005 to about 5 percent by weight, preferably from about 0.01 to about 4 percent by weight.
For example, the growth factor comprises a share of about 0.05 to about 2 percent by weight, preferably from about 0.1 to about 5 percent by weight, preferably from about 0.5 to about 3 percent by weight.
The device in related embodiments includes at least one scaffold material, preferably a scaffold material having an osteo-conductive activity. For example, the scaffold is collagen having an amino acid sequence substantially identical to a human collagen.
Further, the collagen is recoinbinantly produced. Alternatively or in addiction, the scaffold material is at least one selected from the group of ceramics, biologically compatible metals and biologically compatible polymers. The device can further include at least one additional active substance selected from the group of at least one cytostatic agent and/or at least one antibiotic.
Alternatively, the device can further include at least one component selected from the group of:
a recruiting factor, an adhesion factor, a growth factor and a maturation factor for osteogenesis or chondrogenesis. The device in general is a co-lyophil or a co-granulate and is a spongy form-stable body that comprises pores. The pores have a diameter in the range of about 100 m to about 300 m, and such that the admixture has a consistency and stable form of a surgical sponge. The device admixture in related embodiments is at least partially bio-resorbable, and is preferably completely bio-resorbable. The admixture is generally aseptically prepared from aseptic or sterile components. The device in various embodiments is proyided in a closed container. In a particular embodiment, the admixture is aseptically lyophilized in the container.
For example, the container is aseptically covered with a material capable of unidirectional passage of solvent molecules during lyophililization.
In general the scaffold material includes human recombinant collagen. For example, the collagen is selected from at least one of a type I collagen and a type III
collagen. Alternatively or in addition, the scaffold material comprises a mineral. For example, the mineral is selected from the group consisting of: tricalcium phosphate, ceramic materials, biologically compatible metals, and biologically compatible polymers. In certain embodiments, the device includes collagen that is cross-linked using a commonly known reagent for cross-linking proteins. For example, the collagen is covalently internally cross-linked to itself, or the collagen is covalently linked to the growth factor. Thus the collagen is covalently cross-linked in solution to the growth factor to obtain a matrix, and then the matrix is lyophilized aseptically and used as an implant in a subject for treatment of a bone and/or a cartilage defect.
Accordingly, following implant into the subject, the matrix is subsequently metabolized releasing slowly the covalently bound growth factor such as BMP-2 or BMP-7, compared to release of an otherwise identically constituted and non-covalently bound matrix releasing growth factor in a burst at an early time point following implant into the subject.
In certain embodiments of the device, the covalently cross linked collagen is obtained by contacting the collagen and osteo- and/or chondro-stimulating factors with a bidentate, low molecular cross-linking reagent selected from the group of commonly used in protein and peptide chemistry reagents: 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), succinic anhydride, a di-isocyanates, an activated and properly protected amino acids, a double activated polyethylene-glycol, and an activated carbon hydrate to obtain quantitative binding of the reagent to the collagen.
Accordingly, the device, following quantitative binding of the reagent to collagen is further prepared by the steps of: removing excess reagent by dialyzing, to obtain a modified collagen that retains protein features having a biological activity selected from the group of osteo-inductive, chondro-inductive, osteo-conductive and chrondo-conductive; mixing the modified collagen with the factor/s for a time appropriate for cross-linking; and lyophilyzing, such that the steps are perforined aseptically. The device in embodiments above includes materials that are aseptic, such that the device has a reduced microbial content.
In yet another embodiment, the device contains at least one additional component that retards release of the growth factor from the scaffold, for example from the collagen. The additional component retards release of the growth factor by non-covalent affinity, for example, the additional component is a plasma protein such as fibrin or a globulin. The additional component is in related embodiments of human origin, and/or is recombinantly produced.
Detailed Description A problem in treatment of bone and cartilage defects is that certain synthetic materials currently used to repair bone defects are poorly absorbed or are non-bioresorbable. These include ceramic materials, for example porous calcium phosphate ceramics. Such materials have useful osteo-conductive properties, i.e., the materials are able to provide regenerating bone tissue with a structure creating matrix (guide structure) with sufficient mechanical stability.
Bone generating cells bind to materials with osteo-conductive properties, and then precipitate a bone matrix around or inside this material. Ceramic materials, however, remain in an unchanged state in the body, and are consequently overgrown and penetrated by the newly generated bone.
Bioresorbable bone replacement materials include synthetic polymers such as polylactide and polyglycolide. Such synthetic materials are degraded in vivo, usually by hydrolysis.
Degradation of these materials can lead to a release of acidic by-products such as lactic acid or glycolic acid, causing undesired local hyper-acidification in the body.
Bone replacement materials currently used to repair bone defects include extracts of natural bone, such as bovine bone, porcine bone, or equine bone. Demineralized bone is a natural bone material in which the inorganic portion (mineral portion) has been removed and the remaining organic matrix substantially retains the natural endogenous collagen with other additional proteins. The extract retains a portion of the functional properties of the original bone. Further, these extracts of bone are found to enhance repair of bone defects.
Bone replacement materials and methods of manufacturing thereof, are shown in for example WO 91/06324 Al and WO 93/20857 Al, and are commercially available products COLLOSS and COLLOSS E, which are collagen extracts of bovine bone and equine (E) bone respectively. These products contain collagen type I of animal origin in combination with endogenous growth and differentiation factors retained and bound to the collagen.
COLLOSS and COLLOSS E are provided in the form of a lyophilized extract.
These products show osteo-conductive and osteo-inductive activity, and have a further differentiating activity when contacted to stem cells. The term, "osteo-inductivity" as used herein means that the substance or material initiates regeneration of bone (osteogenesis) and stimulates regeneration of bone (osteo-stimulation), and thus promotes bone growth. The regeneration activity has been demonstrated in vivo, and also in cell culture ex vivo.
Under certain circumstances, materials having these properties can be manipulated to amplify the regeneration process compared to normal bone growth. The osteo-conductive effects of each of the above products, however, are not sufficient for certain applications.
Similar considerations apply to cartilage defects and to remedies for cartilage defects.
The term, "chondro-inductivity" as used herein means that the substance or material initiates regeneration of cartilage (chondrogenesis) and stimulates regeneration of cartilage (chondro-stimulation), and thus promotes cartilage growth.
A complex for growth of bone tissue that includes a bone derived component, a bone derived chemotactic component, a bone derived adhesion component, and a bone derived growth factor is shown in WO 91/06324 Al (corresponding to U.S. patent number 5,932,207 issued August 3, 1999) which is herein incorporated by reference in its entirety.
This patent shows examples of the adhesion component, fibronectin, tenascin, cytotactin, laminin, chondroinectin, collagen types IV, V, VII, N-CAM, L-CAM, and integrin, however without a filling agent that increases the osteo-conductive effect as well as an osteo-inductive effect of the complex.
Osteogenic compositions are shown in Chen et al. (U.S. patent numbers 5,707,962, issued January 13, 1998, and 6,180,606, issued January 30, 2001). Osteogenic devices are shown in Opperman et et al. (U.S. patent numbers 5,958,441, issued September 28, 1999, and 6,551,995, issued Apri122, 2003).
The compositions and devices provided herein contain a structural component having osteo-inductive and/or osteo-conductive properties, such as collagen, for example a collagen of animal origin. The animal origin of the collagen contained in the coinposition and device provided herein is not Iimiting. In certain embodiments of the device and composition herein, the collagen of the composition is of human origin, and contains at least one osteo-inductive or chondro-inductive active substance of human origin. In alternative embodiments, the collagen is of non-human animal origin, for example of bovine, porcine or equine origin.
The devices and compositions further include at least one additive of at least one differentiation and/or growth factor, having osteo-stimulative and/or chondro-stimulative activity. These differentiation and/or growth factors are, for example, proteins or peptides, such as cytokines, glycoproteins or glycopeptides.
In certain embodiments, the differentiation and/or growth factors are primarily human differentiation or growth factors and are combined with human collagen. In alternative embodiments, the human differentiation or growth factor is combined in the device with a collagen of xenogenic origin (in relation to human), i.e., of non-human animal origin, for example, bovine, porcine or equine origin.
In general, the differentiation or growth factor of human or animal origin is recombinantly produced. The term "recombinant" refers to proteins produced by manipulation of genetically modified organisms, for example micro-organisms.
In accordance with the present invention, polynucleotide sequences that encode differentiation or growth factors are used in recombinant DNA molecules to direct the expression of the differentiation or growth factors in appropriate host cells.
To express a biologically active human differentiation or growth factor, a nucleotide sequence encoding the differentiation or growth factor, or functional equivalent, is inserted into an appropriate expression vector, i.e., a vector that contains the necessary nucleic acid encoding elements that regulate transcription and translation of the inserted coding sequence.
Methods that are well known to those skilled in the art are used to construct expression vectors containing a sequence encoding the differentiation or growth factor and appropriate transcriptional or translational controls. These methods include in vitro recombinant DNA
techniques, synthetic techniques and in vivo recombination or genetic recombination.
Introduction of deletions, additions, or substitutions is achieved using any known technique in the art e.g., using PCR based mutagenisis. Such techniques are described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, 1989 and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, 1989.
A variety of expression vector/host systems are utilized to contain and express a human differentiation or growth factor encoding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transfected with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (e.g., Ti, pBR322, or pET25b plasmid);
or animal cell systems. Alternatively, chemical methods are used to synthesize the differentiation or growth factor amino acid sequence, whole or in part. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge et al., Science 269:202, 1995) and automated synthesis may be achieved, for example, using the 43 1A peptide synthesizer (available from Applied Biosystems of Foster City, CA) in accordance with the instructions provided by the manufacturer.
The differentiation or growth factor in another embodiment is at least one member of the TGF (Transforming Growth Factor) family. TGF family growth factors include, for example, various cytokines such as members of the TGF-(3 family, that include the BMP
family (Bone Morphogenetic Proteins), for example, BMP-2 and BMP-7. In certain embodiments, the differentiation and/or growth factor is BMP granulated with for example polylactide (micro capsules).
BMP compositions of human origin and of bovine origin, and processes of isolating BMP compositions and factors are shown in Urist (U.S. patent number 4,619,989, issued October 28, 1986).
For BMP-2, the nucleic acid sequence, amino acid sequence, structure, and composition of BMP-2, and methods of manufacture are shown in Wang et al. (U.S. patent number 5,631,142, issued May 20, 1997). Purified BMP-2 and BMP-4 proteins and processes for producing them are shown in Wang et al. (U.S. patent application number 2007/0026437, published February 1, 2007). Methods of production of recombinant BMP-2 are shown in Rainer et al. (U.S. patent application number 20040018595, published January 29, 2004).
Recombinant human BMP-2 is also commercially available from Shenandoah Biotechnology, Inc. (Warwick, PA).
Purified BMP-7 proteins and processes for producing them are shown in Wozney et al.
(U.S. patent number 5,366,875, issued November 22, 1994). DNA sequences encoding BMP-7 proteins are shown in Rosen et al. (U.S. patent number 5,141,905, issued August 25, 1992).
Recombinant human BMP-7 is also commercially available from Shenandoah Biotechnology, Inc. (Warwick, PA).
Each of the above references is incorporated by reference in its entirety.
Additional suitable differentiation or growth factors that are used in compositions and devices herein include VEGF (Vascular Endothelial Growth Factor), IGF1 (Insulin Growth Factor 1), FGF (Fibroblast Growth Factor) and PDGF (Platelet Derived Growth Factor).
Alternatively, a functional fragment of any of the above mentioned differentiation or growth factor is used. The term "functional fragment" refers to molecules of a modified structure and/or sequence that provide the same biological function as the above mentioned differentiation or growth factors. Functional fragments include proteins that contain naturally occurring or engineered alterations, including any of a deletion, an addition, a substitution or other modification. A functional fragment is exemplified by a protein having a naturally occurring sequence for a region of any of the above mentioned differentiation or growth factors by a corresponding region of a growth factor from another malnmalian species, including but not limited to, bovine, canine, feline, caprine, ovine, porcine, murine, and equine species.
The term "substantially identical" is used herein to refer to a first amino acid sequence that contains a sufficient or minimum number of amino acid residues that are identical to aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structural domain and/or common functional activity. For example, amino acid sequences that contain a common structural domain having at least about 60%, or 65% identity, preferably at least 75% identity, more preferably at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity.
Calculations of sequence identity between sequences are performed as follows.
To determine the percent identity of two amino acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid sequence for optimal alignment). The amino acid residues at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the proteins are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
The comparison of sequences and determination of percent identity between two sequences are accomplished using a mathematical algorithm. Percent identity between two amino acid sequences is determined using an alignment software program using the default parameters. Suitable programs include, for example, CLUSTAL W by Thompson et al., Nuc.
Acids Research 22:4673, 1994 (www.ebi.ac.uk/clustalw), BL2SEQ by Tatusova and Madden, FEMS Microbiol. Lett. 174:247, 1999 (www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.htm1), SAGA by Notredame and Higgins, Nuc. Acids Research 24:1515, 1996 (igs-server.cnrs-mrs.fr/-cnotred), and DIALIGN by Morgenstern et al., Bioinformatics 14:290, 1998 (bibiserv.techfak.uni-bielefeld.de/dialign).
In certain embodiments, the device or composition provided herein is engineered to provide for slow time-release of the active agents. For example, the device or composition further includes at least one additional component capable of retarding release of the differentiation or growth factor from the composition. Retarding release components are, for example a "sticky" protein capable of substantial non-specific binding, such as a protamine and a plasma protein such as globulin, albumin, and fibrin. Protamine is an alkaline protein extracted from fish sperm and has a molecular weight of about 5000 Daltons. In an alternative embodiment for retarding release, the growth or differentiation factor is covalently bound to the collagen, for example by a protein cross-linking agent.
In certain embodiments of the invention provided herein, the device or composition further includes at least one filler or filling material. The filling or filler material has several purposes, such as providing the composition with additional mechanical stability and/or stability of form or shape. In general, the filling material has osteo-conductive properties, and provides additional surfaces for cell proliferation and/or cell differentiation.
The devices or compositions that contain filling materials such as collagen and at least one osteo-inductive or chondro-inductive active substance are manufactured to specific quantities of each component in the composition. Relative to the amount of collagen, the osteo-inductive or chondro-inductive active substance is contained in an amount of about 0.005 to about 5.0 mass percent, for example about 0.01 to about 4.0 xnass percent. In other embodiments, the additive is contained in an amount of about 0.05 to about 2.0 mass percent, for example about 0.1 to about 5.0 mass percent or about 0.5 to about 3.0 mass percent.
The filling material is typically collagen, such as type I collagen. The collagen is obtained from skin, tendon, and/or from bone tissue. In certain embodiments, the collagen is of non-human origin, and the tendon is animal tendon, such as equine tendon. In alternative embodiments, the collagen is a recombinantly produced collagen, for example, recombinantly produced human collagen. Further, non-collagen filling materials are within the scope of the compositions and devices herein. Such filling materials are usually contained in the devices herein in the same amounts and proportions as the collagen relative to the osteo-inductive or chondro-inductive active substance.
Additional filling materials suitable to the compositions and devices herein include ceramic materials, biologically compatible metals, and biologically compatible polymers.
Ceramic materials include tricalciumphosphate (TCP), hydroxyapatite (HA), calcium sulfate, CMC (carboxyl methyl cellulose), sepharose, polyarylate, and mixtures of such materials. In certain embodiments, the filling material is a(3-tricalciumphosphate. Such filling materials are, present in the compositions and devices herein in relation to the total volume of the remaining elements, at least about 50 volume percent, at least about 80 volume percent, at least about 95 volume percent, or at least about 99 volume percent.
Ceramic filling materials are useful because the ionogenic elements of such materials, i.e., the fixed group of atoms in an ion exchanger that are either ionized or capable thereof, constitute the main elements of natural bone and mineral bone substance, and are therefore suitable bio-mimetic materials.
Ceramic material is used as a filling material in the commercially available product OSSAPLAST" (commercially available from Ossacur, Stuttgart, Germany). This product includes a bioresorbable and granulated (3-tricalciumphosphate with a high interconnecting porosity and a large specific surface.
Filling material is further exemplified by a biologically compatible metal.
Examples of biologically compatible metals are magnesium, titanium and tantalum. Further, magnesium is also bioresorbable. Examples of biologically compatible polymers include synthetic polymers such as polylactide and polyglycolide. The filler agent in other embodiments is a derivative of native bone, for example, demineralized bone matrix (DBM).
In certain einbodiments, the filler agent provides additional osteo-inductive or chondro-inductive activity to the composition and/or device herein. These filler materials include leukotrienes, cytotactin, tenascin, laminin, fibronectin and cytokines such as BMP-1, BMP-2, BMP-7, IGF-1, TGF-(31, FGF and PDGF.
In embodiments of methods of manufacture of the devices and compositions, the filler material is added to a collagen matrix by modifying the collagen prior to the addition. For example, the collagen is chemically modified so that the filling material is covalently cross-linked to the collagen. In an alternative embodiment, the filling material is added prior to preparation of the collagen matrix, or is a naturally occurring factor in the corresponding collagen matrix, i.e., the collagen and the filling material are combined by the process by which they are provided, for example, the growth factor is extracted from its biological source, viz., natural bone. In this embodiment, the osteo-inductive or chondro-inductive filling materials are present in a native form in association with the collagen.
One or more additional agents that provide a further desired biological effect with respect to treating bone or cartilage defects is added in other embodiments of the devices and compositions provided herein. Such additional agents are, for example, a cytostatic agent or an antibiotic, or a combination thereof.
In another embodiment, the device or composition further includes recruiting factors, for example a chemotactic agent (such as a chemotaxin or a leucotriene). The recruiting factor induces an infiltration of the composition into cells of a human, such as mesenchymal stem cells, cartilage premonitory stem cells, fibroblasts and/or thrombocytes.
Alternatively these substances are added to the collagen, or are supplemented.
In another embodiment, the collagen contained in the composition further includes at least one adhesion factor, for example cytotactin, tenascin, laminin and/or fibronectin. These substances function to fix recruited or migrant cells in the composition or device according to the invention at its application location (implant location).
In certain embodiments, the above mentioned factors are naturally found in collagen, such that the filling material can be purified, or can be obtained in a complex that is a mixture of a plurality of these factors. The collagen component of the composition or device can include a substantial portion of the osteo-inductive properties of the filling materials that are involved in vivo for regeneration of bone and/or cartilage. A set of the naturally occurring filling materials mentioned above can have overlapping or redundant active functions, such that a partial or substantial loss of activity of one or more active substances may be compensated by the presence of other active substances in the composition.
Collagen of animal origin is commercially available in isolation form, e.g., COLLOSS"
(bovine) and COLLOSS E (equine) from Ossacur (Oberstenfeld, Germany). These products contain native active substances, so that the combination of the collagen and active substance provides a native, functional unit, the composition corresponding in a particular manner to the in vivo milieu, in which bone and/or cartilage regeneration is induced.
Methods of extracting collagen from natural bone are well known in the art.
Collagen is extracted from natural bone by the following exemplary procedure: pulverizing natural bone;
degreasing by extraction with an organic solvent; demineralizing with acid treatment, for example hydrochloric acid; incubating with chelating agents, for example ethylenediamine tetraacetic acid (EDTA) or 2-amino-2-hydroxymethyl-1,3-propanediol (TRIS) or a combination thereof; and extracting with guanidine, for example guanidine hydrochloride;
followed by purifying the extract; and physically forming the extract into a configuration suitable for implanting. One of ordinary skill in the art of biology will understand that one or more of the above steps may be omitted as necessary or additional steps are within exemplary procedures.
In certain embodiments, the composition or device is in a porous configuration or form.
In other embodiments, the device or composition has a substantially spongy consistency. The type filling material, as described above such as, ceramic materials, e.g., tricalciumphosphate (TCP), determines the extent of porosity of the composition or device.
In certain embodiments, the porosity is an interconnecting porosity, i.e., the pore structure is located between the individual particles of the filling material, and within the particles. A porous device or composition is advantageous for cell infiltration from cells of the subject recipient of the implant into the pores of the device or composition, for example bone and/or cartilage cells, or progenitor cells thereof.
Pores of the composition or device or the pores of the filling material, respectively, have diameters of at least about 100 m, particularly diameters of about 100 m to about 300 m. In certain embodiments, the pores of the composition or device or the pores of the filling material, respectively are about 200 m in diameter.
In certain embodiments, the composition and device according to the invention is at least partly bio-resorbable. In a related embodiment, the composition and device according to the invention is completely bioresorbable. Following implantation, the implant to treat the bone or cartilage defect is completely replaced by new bone or new cartilage.
In another embodiment, the composition according to the invention is a lyophil, for example colyophil. The advantages of a lyophil are described in the Examples below.
In another embodiment, the composition according to the invention is a substantially form-stable body, for example, a porous spongy structure with sufficient mechanical stability to withstand mechanical manipulation involved with implantation. Such a composition includes osteo-inductive/chondro-inductive properties for regeneration of bone or cartilage.
In general, the composition and/or device provided herein is produced in an aseptic or sterile procedure and is packed in a sterile procedure. Further, the device is unitary and requires no manipulation so it can be implanted directly for the treatment of the bone or cartilage defect without additional preparation.
Another aspect of the present invention provides a new method for manufacturing the above described composition according to the invention. The method involves providing a collagen, for example a collagen of human origin, recombinant coliagen, or a collagen of animal origin, which includes at least one osteo-inductive or chondro-inductive active substance;
mixing this collagen with an additive of at least one differentiation or growth factor with osteo-stimulative and/or chondro-stiinulative effect and possibly other substances;
and colyophilizing these components to form an at least partially stable spongy body.
In certain embodiments of the method according to the invention, prior to mixing the collagen with the at least one additive, the collagen is treated with at least one peptidase, for example an endopeptidase such as trypsin. Treating with an endopeptidase removes undesired proteins or peptides, for example. telopeptides that are found in the collagen (with or without active substance), are removed from this collagen fraction. In general, the endopeptidase used in the described treatment, such as trypsin, is provided in such an amount that it is depleted or completely removed before affecting the osteo-conductive activity of the collagen fraction. One of ordinary skill in the art of biochemistry determines appropriate concentrations of the endopeptidase and duration of treatment to the mixture that does not affect the activity of the collagen fraction. In other embodiments, collagen, for example type I
collagen, is not digested by an endopeptidase.
In other embodiments of the method, the collagen is concentrated prior to mixing the collagen with the additional one or more compounds. Concentrating the collagen prior to mixing the collagen with additional components is beneficial under certain circumstances with respect to properties of the resulting colyophilized spongy body.
Concentrating the collagen fraction with added osteo-inductive or chondro-inductive active substances provides that the concentration of the active substances in the total device having the collagen fraction together with the active substances of the additive, is great enough to substantially provide a sufficient concentration of the active substances within the total volume of the composition, for example, the spongy body.
Concentrating a mixture having endogenous or added osteo-inductive or chondro-inductive active substances is accomplished by methods well known to one of ordinary skill in the art in biology. For example, concentrating involves at least one centrifuging step, at least one separation step through a suitable membrane, and/or at least one precipitation step by means of gravity. An exemplary concentration of a protein-containing suspension of the product COLLOSS" E with a dry substance content (TS) of 1.5 mg protein/g to 2.0 mg protein/g suspension. The above described methods result in an increased TS content between 2.0 mg protein/g to 20.0 mg protein/g suspension.
In general, a resulting spongy body provides the user with a homogeneous distribution of the biologically active substances that form the spongy body. In general, the filling materials constitute a larger volume of the spongy body than the biological materials.
The biological materials obtained from collagen and from added agents such as differentiation or growth factors only cover the volume between the particles of the filling materials.
In certain embodiments, collagen is mixed with a porous filling material with osteo-conductive properties, as described above. An exemplary process for obtaining collagen with osteo-conductive properties involves mixing collagen and an above mentioned filling material with osteo-conductive properties. During this mixing, the collagen is applied as a coating on the inner and outer surfaces of the porous filling material with osteo-conductive properties. Further steps include lyophilizing the resulting mixture to obtain collagen with osteo-conductive properties, i.e., collagen having an osteo-inductive/osteo-stimulative or chondro-inductive/chondro-stimulative effect. The method further provides at least one collagen with osteo-inductive or chondro-inductive, active substance and/or an additive of at least one differentiation or growth factor with osteo-stimulative and/or chondro-stimulative effect. The resulting mix is finally colyophilized to form a substantially stable spongy body.
In general, the method described above is performed under aseptic conditions, yielding a resulting device or composition according to the invention that is in aseptic or even sterile. In alternative embodiments, a variety of sterilization methods are used to obtain the composition that is aseptic or is sterile. In one embodiment, prior to use in the method according to the invention, each individual component of the composition according to the invention is sterilized, for example, filtered under sterile conditions to remove bacteria and viruses.
In another embodiment, the method further includes packaging the composition or device in a sterile manner to provide an aseptic composition or device or a sterile coinposition or device.
The characteristics of the composition according to the invention shown herein are explicitly made characteristics of the method according to the invention and the use according to the invention, respectively.
In the devices provided herein, presence of at least one differentiation and/or growth factor with osteo-stimulative and/or chondro-stimulative effect with at least one collagen results in several advantages, as shown below. Each of the agents induces and also amplifies the osteogenic or chondrogenic properties of the device of the present invention.
Further, presence of growth factor with the collagen results in amplification of already existing form stability of the composition. The composition herein is optimized by interaction between the osteo-inductive and osteo-conductive effect provided by the growth factor, and the form stability/supporting function provided by the filling material. In another embodiment, any reduction of osteo-inductive effect of the composition resulting from addition of filling materials that are not osteo-inductive is compensated or overcome by relatively small increases in the amount of the additive to the composition.
Further, colyophilization in the production process, produces a finalized composition, i.e., the components of the composition are already mixed to form a ready-to-use device.
Another embodiment provides a ready-to-use device that is convenient for use, for example by a surgeon. Because the composition is produced in a sterile manner, it can be taken directly from a sterile package and used during surgery to repair a bone or cartilage defect.
The invention having now been fully described, it is further illustrated by the following examples and claims, which are illustrative and are not meant to be further limiting. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are within the scope of the present invention and claims. The contents of all references, including issued patents and published patent applications cited throughout this application, are hereby incorporated by reference.
Examples Example 1: Production of compositions according to the invention The following method is used for production of the compositions according to the invention.
The product COLLOSS E, a collagen extract of equine bone tissue, is commercially available as described above. Methods of making this product are also described above and are shown in WO 93/20857 Al, which is herein incorporated by reference in its entirety. See also Spine 30:890-895, 2005. This material contains an active substance complex of naturally bound factors in a matrix of type I collagen.
COLLOSS E is available in the form of an aqueous suspension, which is concentrated by performing at least one separation step. The suspension obtained from the concentration is then mixed with further additives and elements of the composition. After obtaining a homogenous mixture, the elenients of this mixture are colyophilised. A porous, spongy, stable body occurs.
To obtain a sterile or aseptic device, the entirety of the steps in the production process are performed under aseptic conditions, and the individual components of the composition are filtered in a sterile manner in advance of their use in the manufacturing process.
Example 2: Compositions of the invention Compositions according to the invention are prepared from the following elements:
No. Collagen matrix Additive Further additives 1 5 mg COLLOSS E 0.01 mg human -BMP-2 (or BMP-7) 2 5 mg COLLOSS E 2 mg human BMP- -2 (or BMP-7) 3 100 mg COLLOSS E 0.01 mg human -BMP-2 (or BMP-7) 4 100 mg COLLOSS E 2 mg human BMP- -2 (or BMP-7) No. 1- No. 4 No. 1- No. 4 1 ml TCP* (OSSAPLAST) 6 No. 1-No. 4 No. 1 -No. 4 1 ml TCP (OSSAPLAST) 5 mg collagen type I
7 No. 1-No. 4 No. 1 -No. 4 1 ml TCP (OSSAPLAST) 100 mg collagen type I
8 - 0.01 mg human 1 ml TCP (OSSAPLAST) 5 BMP-2 (or BMP-7) - 100 mg collagen type I
9 - 2 mg human 1 ml TCP (OSSAPLAST) 5 BMP-2 (or BMP-7) - 100 mg collagen type I
5 *Tricalcium phosphate Further examples of agents that, in certain embodiments are present in the devices and compositions of the invention include: BMP colyophilized with collagen and/or ceramic; BMP
bound with a spacer (globulin, polyethylene glycol (PEG), albumin, protamine, and fibrin) to the collagen; and a suspension of collagen with a protamine, a globulin, a fibrin, an albumin, and BMP and the suspension is then lyophilized. -The BMP-2 or BMP-7 or other growth factors in the device or composition are for example a recombinantly produced human protein. The collagen type I used is for example a recombinant huinan collagen. Use of recombinant human BMP-2 or BMP-7 and recombinant human collagen is advantageous when administering these compositions to human beings because of severe antigenic activity of xenobiotic proteins.
Degradation of these materials can lead to a release of acidic by-products such as lactic acid or glycolic acid, causing undesired local hyper-acidification in the body.
Bone replacement materials currently used to repair bone defects include extracts of natural bone, such as bovine bone, porcine bone, or equine bone. Demineralized bone is a natural bone material in which the inorganic portion (mineral portion) has been removed and the remaining organic matrix substantially retains the natural endogenous collagen with other additional proteins. The extract retains a portion of the functional properties of the original bone. Further, these extracts of bone are found to enhance repair of bone defects.
Bone replacement materials and methods of manufacturing thereof, are shown in for example WO 91/06324 Al and WO 93/20857 Al, and are commercially available products COLLOSS and COLLOSS E, which are collagen extracts of bovine bone and equine (E) bone respectively. These products contain collagen type I of animal origin in combination with endogenous growth and differentiation factors retained and bound to the collagen.
COLLOSS and COLLOSS E are provided in the form of a lyophilized extract.
These products show osteo-conductive and osteo-inductive activity, and have a further differentiating activity when contacted to stem cells. The term, "osteo-inductivity" as used herein means that the substance or material initiates regeneration of bone (osteogenesis) and stimulates regeneration of bone (osteo-stimulation), and thus promotes bone growth. The regeneration activity has been demonstrated in vivo, and also in cell culture ex vivo.
Under certain circumstances, materials having these properties can be manipulated to amplify the regeneration process compared to normal bone growth. The osteo-conductive effects of each of the above products, however, are not sufficient for certain applications.
Similar considerations apply to cartilage defects and to remedies for cartilage defects.
The term, "chondro-inductivity" as used herein means that the substance or material initiates regeneration of cartilage (chondrogenesis) and stimulates regeneration of cartilage (chondro-stimulation), and thus promotes cartilage growth.
A complex for growth of bone tissue that includes a bone derived component, a bone derived chemotactic component, a bone derived adhesion component, and a bone derived growth factor is shown in WO 91/06324 Al (corresponding to U.S. patent number 5,932,207 issued August 3, 1999) which is herein incorporated by reference in its entirety.
This patent shows examples of the adhesion component, fibronectin, tenascin, cytotactin, laminin, chondroinectin, collagen types IV, V, VII, N-CAM, L-CAM, and integrin, however without a filling agent that increases the osteo-conductive effect as well as an osteo-inductive effect of the complex.
Osteogenic compositions are shown in Chen et al. (U.S. patent numbers 5,707,962, issued January 13, 1998, and 6,180,606, issued January 30, 2001). Osteogenic devices are shown in Opperman et et al. (U.S. patent numbers 5,958,441, issued September 28, 1999, and 6,551,995, issued Apri122, 2003).
The compositions and devices provided herein contain a structural component having osteo-inductive and/or osteo-conductive properties, such as collagen, for example a collagen of animal origin. The animal origin of the collagen contained in the coinposition and device provided herein is not Iimiting. In certain embodiments of the device and composition herein, the collagen of the composition is of human origin, and contains at least one osteo-inductive or chondro-inductive active substance of human origin. In alternative embodiments, the collagen is of non-human animal origin, for example of bovine, porcine or equine origin.
The devices and compositions further include at least one additive of at least one differentiation and/or growth factor, having osteo-stimulative and/or chondro-stimulative activity. These differentiation and/or growth factors are, for example, proteins or peptides, such as cytokines, glycoproteins or glycopeptides.
In certain embodiments, the differentiation and/or growth factors are primarily human differentiation or growth factors and are combined with human collagen. In alternative embodiments, the human differentiation or growth factor is combined in the device with a collagen of xenogenic origin (in relation to human), i.e., of non-human animal origin, for example, bovine, porcine or equine origin.
In general, the differentiation or growth factor of human or animal origin is recombinantly produced. The term "recombinant" refers to proteins produced by manipulation of genetically modified organisms, for example micro-organisms.
In accordance with the present invention, polynucleotide sequences that encode differentiation or growth factors are used in recombinant DNA molecules to direct the expression of the differentiation or growth factors in appropriate host cells.
To express a biologically active human differentiation or growth factor, a nucleotide sequence encoding the differentiation or growth factor, or functional equivalent, is inserted into an appropriate expression vector, i.e., a vector that contains the necessary nucleic acid encoding elements that regulate transcription and translation of the inserted coding sequence.
Methods that are well known to those skilled in the art are used to construct expression vectors containing a sequence encoding the differentiation or growth factor and appropriate transcriptional or translational controls. These methods include in vitro recombinant DNA
techniques, synthetic techniques and in vivo recombination or genetic recombination.
Introduction of deletions, additions, or substitutions is achieved using any known technique in the art e.g., using PCR based mutagenisis. Such techniques are described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, 1989 and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, 1989.
A variety of expression vector/host systems are utilized to contain and express a human differentiation or growth factor encoding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transfected with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (e.g., Ti, pBR322, or pET25b plasmid);
or animal cell systems. Alternatively, chemical methods are used to synthesize the differentiation or growth factor amino acid sequence, whole or in part. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge et al., Science 269:202, 1995) and automated synthesis may be achieved, for example, using the 43 1A peptide synthesizer (available from Applied Biosystems of Foster City, CA) in accordance with the instructions provided by the manufacturer.
The differentiation or growth factor in another embodiment is at least one member of the TGF (Transforming Growth Factor) family. TGF family growth factors include, for example, various cytokines such as members of the TGF-(3 family, that include the BMP
family (Bone Morphogenetic Proteins), for example, BMP-2 and BMP-7. In certain embodiments, the differentiation and/or growth factor is BMP granulated with for example polylactide (micro capsules).
BMP compositions of human origin and of bovine origin, and processes of isolating BMP compositions and factors are shown in Urist (U.S. patent number 4,619,989, issued October 28, 1986).
For BMP-2, the nucleic acid sequence, amino acid sequence, structure, and composition of BMP-2, and methods of manufacture are shown in Wang et al. (U.S. patent number 5,631,142, issued May 20, 1997). Purified BMP-2 and BMP-4 proteins and processes for producing them are shown in Wang et al. (U.S. patent application number 2007/0026437, published February 1, 2007). Methods of production of recombinant BMP-2 are shown in Rainer et al. (U.S. patent application number 20040018595, published January 29, 2004).
Recombinant human BMP-2 is also commercially available from Shenandoah Biotechnology, Inc. (Warwick, PA).
Purified BMP-7 proteins and processes for producing them are shown in Wozney et al.
(U.S. patent number 5,366,875, issued November 22, 1994). DNA sequences encoding BMP-7 proteins are shown in Rosen et al. (U.S. patent number 5,141,905, issued August 25, 1992).
Recombinant human BMP-7 is also commercially available from Shenandoah Biotechnology, Inc. (Warwick, PA).
Each of the above references is incorporated by reference in its entirety.
Additional suitable differentiation or growth factors that are used in compositions and devices herein include VEGF (Vascular Endothelial Growth Factor), IGF1 (Insulin Growth Factor 1), FGF (Fibroblast Growth Factor) and PDGF (Platelet Derived Growth Factor).
Alternatively, a functional fragment of any of the above mentioned differentiation or growth factor is used. The term "functional fragment" refers to molecules of a modified structure and/or sequence that provide the same biological function as the above mentioned differentiation or growth factors. Functional fragments include proteins that contain naturally occurring or engineered alterations, including any of a deletion, an addition, a substitution or other modification. A functional fragment is exemplified by a protein having a naturally occurring sequence for a region of any of the above mentioned differentiation or growth factors by a corresponding region of a growth factor from another malnmalian species, including but not limited to, bovine, canine, feline, caprine, ovine, porcine, murine, and equine species.
The term "substantially identical" is used herein to refer to a first amino acid sequence that contains a sufficient or minimum number of amino acid residues that are identical to aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structural domain and/or common functional activity. For example, amino acid sequences that contain a common structural domain having at least about 60%, or 65% identity, preferably at least 75% identity, more preferably at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity.
Calculations of sequence identity between sequences are performed as follows.
To determine the percent identity of two amino acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid sequence for optimal alignment). The amino acid residues at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the proteins are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
The comparison of sequences and determination of percent identity between two sequences are accomplished using a mathematical algorithm. Percent identity between two amino acid sequences is determined using an alignment software program using the default parameters. Suitable programs include, for example, CLUSTAL W by Thompson et al., Nuc.
Acids Research 22:4673, 1994 (www.ebi.ac.uk/clustalw), BL2SEQ by Tatusova and Madden, FEMS Microbiol. Lett. 174:247, 1999 (www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.htm1), SAGA by Notredame and Higgins, Nuc. Acids Research 24:1515, 1996 (igs-server.cnrs-mrs.fr/-cnotred), and DIALIGN by Morgenstern et al., Bioinformatics 14:290, 1998 (bibiserv.techfak.uni-bielefeld.de/dialign).
In certain embodiments, the device or composition provided herein is engineered to provide for slow time-release of the active agents. For example, the device or composition further includes at least one additional component capable of retarding release of the differentiation or growth factor from the composition. Retarding release components are, for example a "sticky" protein capable of substantial non-specific binding, such as a protamine and a plasma protein such as globulin, albumin, and fibrin. Protamine is an alkaline protein extracted from fish sperm and has a molecular weight of about 5000 Daltons. In an alternative embodiment for retarding release, the growth or differentiation factor is covalently bound to the collagen, for example by a protein cross-linking agent.
In certain embodiments of the invention provided herein, the device or composition further includes at least one filler or filling material. The filling or filler material has several purposes, such as providing the composition with additional mechanical stability and/or stability of form or shape. In general, the filling material has osteo-conductive properties, and provides additional surfaces for cell proliferation and/or cell differentiation.
The devices or compositions that contain filling materials such as collagen and at least one osteo-inductive or chondro-inductive active substance are manufactured to specific quantities of each component in the composition. Relative to the amount of collagen, the osteo-inductive or chondro-inductive active substance is contained in an amount of about 0.005 to about 5.0 mass percent, for example about 0.01 to about 4.0 xnass percent. In other embodiments, the additive is contained in an amount of about 0.05 to about 2.0 mass percent, for example about 0.1 to about 5.0 mass percent or about 0.5 to about 3.0 mass percent.
The filling material is typically collagen, such as type I collagen. The collagen is obtained from skin, tendon, and/or from bone tissue. In certain embodiments, the collagen is of non-human origin, and the tendon is animal tendon, such as equine tendon. In alternative embodiments, the collagen is a recombinantly produced collagen, for example, recombinantly produced human collagen. Further, non-collagen filling materials are within the scope of the compositions and devices herein. Such filling materials are usually contained in the devices herein in the same amounts and proportions as the collagen relative to the osteo-inductive or chondro-inductive active substance.
Additional filling materials suitable to the compositions and devices herein include ceramic materials, biologically compatible metals, and biologically compatible polymers.
Ceramic materials include tricalciumphosphate (TCP), hydroxyapatite (HA), calcium sulfate, CMC (carboxyl methyl cellulose), sepharose, polyarylate, and mixtures of such materials. In certain embodiments, the filling material is a(3-tricalciumphosphate. Such filling materials are, present in the compositions and devices herein in relation to the total volume of the remaining elements, at least about 50 volume percent, at least about 80 volume percent, at least about 95 volume percent, or at least about 99 volume percent.
Ceramic filling materials are useful because the ionogenic elements of such materials, i.e., the fixed group of atoms in an ion exchanger that are either ionized or capable thereof, constitute the main elements of natural bone and mineral bone substance, and are therefore suitable bio-mimetic materials.
Ceramic material is used as a filling material in the commercially available product OSSAPLAST" (commercially available from Ossacur, Stuttgart, Germany). This product includes a bioresorbable and granulated (3-tricalciumphosphate with a high interconnecting porosity and a large specific surface.
Filling material is further exemplified by a biologically compatible metal.
Examples of biologically compatible metals are magnesium, titanium and tantalum. Further, magnesium is also bioresorbable. Examples of biologically compatible polymers include synthetic polymers such as polylactide and polyglycolide. The filler agent in other embodiments is a derivative of native bone, for example, demineralized bone matrix (DBM).
In certain einbodiments, the filler agent provides additional osteo-inductive or chondro-inductive activity to the composition and/or device herein. These filler materials include leukotrienes, cytotactin, tenascin, laminin, fibronectin and cytokines such as BMP-1, BMP-2, BMP-7, IGF-1, TGF-(31, FGF and PDGF.
In embodiments of methods of manufacture of the devices and compositions, the filler material is added to a collagen matrix by modifying the collagen prior to the addition. For example, the collagen is chemically modified so that the filling material is covalently cross-linked to the collagen. In an alternative embodiment, the filling material is added prior to preparation of the collagen matrix, or is a naturally occurring factor in the corresponding collagen matrix, i.e., the collagen and the filling material are combined by the process by which they are provided, for example, the growth factor is extracted from its biological source, viz., natural bone. In this embodiment, the osteo-inductive or chondro-inductive filling materials are present in a native form in association with the collagen.
One or more additional agents that provide a further desired biological effect with respect to treating bone or cartilage defects is added in other embodiments of the devices and compositions provided herein. Such additional agents are, for example, a cytostatic agent or an antibiotic, or a combination thereof.
In another embodiment, the device or composition further includes recruiting factors, for example a chemotactic agent (such as a chemotaxin or a leucotriene). The recruiting factor induces an infiltration of the composition into cells of a human, such as mesenchymal stem cells, cartilage premonitory stem cells, fibroblasts and/or thrombocytes.
Alternatively these substances are added to the collagen, or are supplemented.
In another embodiment, the collagen contained in the composition further includes at least one adhesion factor, for example cytotactin, tenascin, laminin and/or fibronectin. These substances function to fix recruited or migrant cells in the composition or device according to the invention at its application location (implant location).
In certain embodiments, the above mentioned factors are naturally found in collagen, such that the filling material can be purified, or can be obtained in a complex that is a mixture of a plurality of these factors. The collagen component of the composition or device can include a substantial portion of the osteo-inductive properties of the filling materials that are involved in vivo for regeneration of bone and/or cartilage. A set of the naturally occurring filling materials mentioned above can have overlapping or redundant active functions, such that a partial or substantial loss of activity of one or more active substances may be compensated by the presence of other active substances in the composition.
Collagen of animal origin is commercially available in isolation form, e.g., COLLOSS"
(bovine) and COLLOSS E (equine) from Ossacur (Oberstenfeld, Germany). These products contain native active substances, so that the combination of the collagen and active substance provides a native, functional unit, the composition corresponding in a particular manner to the in vivo milieu, in which bone and/or cartilage regeneration is induced.
Methods of extracting collagen from natural bone are well known in the art.
Collagen is extracted from natural bone by the following exemplary procedure: pulverizing natural bone;
degreasing by extraction with an organic solvent; demineralizing with acid treatment, for example hydrochloric acid; incubating with chelating agents, for example ethylenediamine tetraacetic acid (EDTA) or 2-amino-2-hydroxymethyl-1,3-propanediol (TRIS) or a combination thereof; and extracting with guanidine, for example guanidine hydrochloride;
followed by purifying the extract; and physically forming the extract into a configuration suitable for implanting. One of ordinary skill in the art of biology will understand that one or more of the above steps may be omitted as necessary or additional steps are within exemplary procedures.
In certain embodiments, the composition or device is in a porous configuration or form.
In other embodiments, the device or composition has a substantially spongy consistency. The type filling material, as described above such as, ceramic materials, e.g., tricalciumphosphate (TCP), determines the extent of porosity of the composition or device.
In certain embodiments, the porosity is an interconnecting porosity, i.e., the pore structure is located between the individual particles of the filling material, and within the particles. A porous device or composition is advantageous for cell infiltration from cells of the subject recipient of the implant into the pores of the device or composition, for example bone and/or cartilage cells, or progenitor cells thereof.
Pores of the composition or device or the pores of the filling material, respectively, have diameters of at least about 100 m, particularly diameters of about 100 m to about 300 m. In certain embodiments, the pores of the composition or device or the pores of the filling material, respectively are about 200 m in diameter.
In certain embodiments, the composition and device according to the invention is at least partly bio-resorbable. In a related embodiment, the composition and device according to the invention is completely bioresorbable. Following implantation, the implant to treat the bone or cartilage defect is completely replaced by new bone or new cartilage.
In another embodiment, the composition according to the invention is a lyophil, for example colyophil. The advantages of a lyophil are described in the Examples below.
In another embodiment, the composition according to the invention is a substantially form-stable body, for example, a porous spongy structure with sufficient mechanical stability to withstand mechanical manipulation involved with implantation. Such a composition includes osteo-inductive/chondro-inductive properties for regeneration of bone or cartilage.
In general, the composition and/or device provided herein is produced in an aseptic or sterile procedure and is packed in a sterile procedure. Further, the device is unitary and requires no manipulation so it can be implanted directly for the treatment of the bone or cartilage defect without additional preparation.
Another aspect of the present invention provides a new method for manufacturing the above described composition according to the invention. The method involves providing a collagen, for example a collagen of human origin, recombinant coliagen, or a collagen of animal origin, which includes at least one osteo-inductive or chondro-inductive active substance;
mixing this collagen with an additive of at least one differentiation or growth factor with osteo-stimulative and/or chondro-stiinulative effect and possibly other substances;
and colyophilizing these components to form an at least partially stable spongy body.
In certain embodiments of the method according to the invention, prior to mixing the collagen with the at least one additive, the collagen is treated with at least one peptidase, for example an endopeptidase such as trypsin. Treating with an endopeptidase removes undesired proteins or peptides, for example. telopeptides that are found in the collagen (with or without active substance), are removed from this collagen fraction. In general, the endopeptidase used in the described treatment, such as trypsin, is provided in such an amount that it is depleted or completely removed before affecting the osteo-conductive activity of the collagen fraction. One of ordinary skill in the art of biochemistry determines appropriate concentrations of the endopeptidase and duration of treatment to the mixture that does not affect the activity of the collagen fraction. In other embodiments, collagen, for example type I
collagen, is not digested by an endopeptidase.
In other embodiments of the method, the collagen is concentrated prior to mixing the collagen with the additional one or more compounds. Concentrating the collagen prior to mixing the collagen with additional components is beneficial under certain circumstances with respect to properties of the resulting colyophilized spongy body.
Concentrating the collagen fraction with added osteo-inductive or chondro-inductive active substances provides that the concentration of the active substances in the total device having the collagen fraction together with the active substances of the additive, is great enough to substantially provide a sufficient concentration of the active substances within the total volume of the composition, for example, the spongy body.
Concentrating a mixture having endogenous or added osteo-inductive or chondro-inductive active substances is accomplished by methods well known to one of ordinary skill in the art in biology. For example, concentrating involves at least one centrifuging step, at least one separation step through a suitable membrane, and/or at least one precipitation step by means of gravity. An exemplary concentration of a protein-containing suspension of the product COLLOSS" E with a dry substance content (TS) of 1.5 mg protein/g to 2.0 mg protein/g suspension. The above described methods result in an increased TS content between 2.0 mg protein/g to 20.0 mg protein/g suspension.
In general, a resulting spongy body provides the user with a homogeneous distribution of the biologically active substances that form the spongy body. In general, the filling materials constitute a larger volume of the spongy body than the biological materials.
The biological materials obtained from collagen and from added agents such as differentiation or growth factors only cover the volume between the particles of the filling materials.
In certain embodiments, collagen is mixed with a porous filling material with osteo-conductive properties, as described above. An exemplary process for obtaining collagen with osteo-conductive properties involves mixing collagen and an above mentioned filling material with osteo-conductive properties. During this mixing, the collagen is applied as a coating on the inner and outer surfaces of the porous filling material with osteo-conductive properties. Further steps include lyophilizing the resulting mixture to obtain collagen with osteo-conductive properties, i.e., collagen having an osteo-inductive/osteo-stimulative or chondro-inductive/chondro-stimulative effect. The method further provides at least one collagen with osteo-inductive or chondro-inductive, active substance and/or an additive of at least one differentiation or growth factor with osteo-stimulative and/or chondro-stimulative effect. The resulting mix is finally colyophilized to form a substantially stable spongy body.
In general, the method described above is performed under aseptic conditions, yielding a resulting device or composition according to the invention that is in aseptic or even sterile. In alternative embodiments, a variety of sterilization methods are used to obtain the composition that is aseptic or is sterile. In one embodiment, prior to use in the method according to the invention, each individual component of the composition according to the invention is sterilized, for example, filtered under sterile conditions to remove bacteria and viruses.
In another embodiment, the method further includes packaging the composition or device in a sterile manner to provide an aseptic composition or device or a sterile coinposition or device.
The characteristics of the composition according to the invention shown herein are explicitly made characteristics of the method according to the invention and the use according to the invention, respectively.
In the devices provided herein, presence of at least one differentiation and/or growth factor with osteo-stimulative and/or chondro-stimulative effect with at least one collagen results in several advantages, as shown below. Each of the agents induces and also amplifies the osteogenic or chondrogenic properties of the device of the present invention.
Further, presence of growth factor with the collagen results in amplification of already existing form stability of the composition. The composition herein is optimized by interaction between the osteo-inductive and osteo-conductive effect provided by the growth factor, and the form stability/supporting function provided by the filling material. In another embodiment, any reduction of osteo-inductive effect of the composition resulting from addition of filling materials that are not osteo-inductive is compensated or overcome by relatively small increases in the amount of the additive to the composition.
Further, colyophilization in the production process, produces a finalized composition, i.e., the components of the composition are already mixed to form a ready-to-use device.
Another embodiment provides a ready-to-use device that is convenient for use, for example by a surgeon. Because the composition is produced in a sterile manner, it can be taken directly from a sterile package and used during surgery to repair a bone or cartilage defect.
The invention having now been fully described, it is further illustrated by the following examples and claims, which are illustrative and are not meant to be further limiting. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are within the scope of the present invention and claims. The contents of all references, including issued patents and published patent applications cited throughout this application, are hereby incorporated by reference.
Examples Example 1: Production of compositions according to the invention The following method is used for production of the compositions according to the invention.
The product COLLOSS E, a collagen extract of equine bone tissue, is commercially available as described above. Methods of making this product are also described above and are shown in WO 93/20857 Al, which is herein incorporated by reference in its entirety. See also Spine 30:890-895, 2005. This material contains an active substance complex of naturally bound factors in a matrix of type I collagen.
COLLOSS E is available in the form of an aqueous suspension, which is concentrated by performing at least one separation step. The suspension obtained from the concentration is then mixed with further additives and elements of the composition. After obtaining a homogenous mixture, the elenients of this mixture are colyophilised. A porous, spongy, stable body occurs.
To obtain a sterile or aseptic device, the entirety of the steps in the production process are performed under aseptic conditions, and the individual components of the composition are filtered in a sterile manner in advance of their use in the manufacturing process.
Example 2: Compositions of the invention Compositions according to the invention are prepared from the following elements:
No. Collagen matrix Additive Further additives 1 5 mg COLLOSS E 0.01 mg human -BMP-2 (or BMP-7) 2 5 mg COLLOSS E 2 mg human BMP- -2 (or BMP-7) 3 100 mg COLLOSS E 0.01 mg human -BMP-2 (or BMP-7) 4 100 mg COLLOSS E 2 mg human BMP- -2 (or BMP-7) No. 1- No. 4 No. 1- No. 4 1 ml TCP* (OSSAPLAST) 6 No. 1-No. 4 No. 1 -No. 4 1 ml TCP (OSSAPLAST) 5 mg collagen type I
7 No. 1-No. 4 No. 1 -No. 4 1 ml TCP (OSSAPLAST) 100 mg collagen type I
8 - 0.01 mg human 1 ml TCP (OSSAPLAST) 5 BMP-2 (or BMP-7) - 100 mg collagen type I
9 - 2 mg human 1 ml TCP (OSSAPLAST) 5 BMP-2 (or BMP-7) - 100 mg collagen type I
5 *Tricalcium phosphate Further examples of agents that, in certain embodiments are present in the devices and compositions of the invention include: BMP colyophilized with collagen and/or ceramic; BMP
bound with a spacer (globulin, polyethylene glycol (PEG), albumin, protamine, and fibrin) to the collagen; and a suspension of collagen with a protamine, a globulin, a fibrin, an albumin, and BMP and the suspension is then lyophilized. -The BMP-2 or BMP-7 or other growth factors in the device or composition are for example a recombinantly produced human protein. The collagen type I used is for example a recombinant huinan collagen. Use of recombinant human BMP-2 or BMP-7 and recombinant human collagen is advantageous when administering these compositions to human beings because of severe antigenic activity of xenobiotic proteins.
Claims (102)
1. A composition for treating bone and/or cartilage defects, comprising at least one collagen, preferably of animal origin, and preferably containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, wherein the composition is in the form of a lyophil.
2. The composition according to claim 1, wherein the at least one differentiation or growth factor is a proteins or peptide, preferably a glycoprotein or glycopeptide, preferably a cytokine.
3. The composition according to claim 1 or 2, wherein the differentiation or growth factor is a human differentiation or growth factor.
4. The composition according to any of the preceding claims, wherein the differentiation or growth factor is recombinantly produced.
5. The composition according to any of the preceding claims, wherein the differentiation or growth factor comprises at least one member of the TGF (Transforming Growth Factor) family.
6. The composition according to claim 5, wherein the differentiation or growth factor comprises at least one member of the group of BMP (Bone Morphogenetic Proteins), preferably BMP-2 and/or BMP-7.
7. The composition according to any of claims 1 to 4, wherein the differentiation or growth factor is a TGF .beta. (Transforming Growth Factor beta) or a VEGF (Vascular Endothelial Growth Factor).
8. The composition according to any of the preceding claims, wherein the differentiation or growth factor in relation to the amount of collagen, osteo-inductive or chondro-inductive activity, comprises a share of about 0.005 to about 5 percent by weight, preferably from about 0.01 to about 4 percent by weight.
9. The composition according to claim 8, wherein the differentiation or growth factor comprises a share of about 0.05 to about 2 percent by weight, preferably from about 0.1 to about 5 percent by weight, preferably from about 0.5 to about 3 percent by weight.
10. The composition according to any of the preceding claims further comprising at least one scaffold material, preferably a scaffold material having osteo-conductive properties.
11. The composition according to claim 10, wherein the scaffold is collagen, preferably type I collagen.
12. The composition according to claim 10, wherein the scaffold material is at least one selected from the group of ceramics, biologically compatible metals and biologically compatible polymers.
13. The composition according to claim 7, wherein the composition has a chondro-inductive activity, and the differentiation or growth factor is TGF.beta..
14. The composition according to any of the preceding claims, wherein the composition further comprises at least one additional active substance, preferably at least one cytostatic and/or at least one antibiotic.
15. The composition according to any of the preceding claims, further comprising at least one component selected from the group of: at least one recruiting factor, at least one adhesion factor, at least one growth factor and at least one maturation factor for osteogenesis or chondrogenesis.
16. The composition according to any of the preceding claims, wherein the collagen is of mammalian origin, preferably of human, bovine, porcine or equine origin.
17. The composition according to any of the preceding claims, further comprising pores, preferably interconnecting pores, preferably pores having a diameter in the range of about 100 µm to about 300 µm, and wherein the composition has a sponge-like consistency.
18. The composition according to any of the preceding claims, wherein the composition is at least partially bioresorbable, preferably completely bio-resorbable.
19. The composition according to any of the preceding claims, further comprising a substantially form-stable body.
20. A composition for treating bone and/or cartilage defects comprising at least one recombinant collagen, preferably of human origin, and preferably containing at least one substance having an osteo-inductive or chondro-inductive activity, wherein the osteo-inductive or chondro-inductive activity is at least one recombinant bone morphogenesis protein (BMP).
21. The composition according to claim 20, wherein the BMP is of mammalian origin, preferably of equine, porcine or bovine origin.
22. The composition according to claim 20 or 21, wherein the BMP is of human origin.
23. The composition according to claim 20 or 21, wherein the BMP has an amino acid sequence that is at least about 70% identical to a BMP of human origin.
24. The composition according to any of the preceding claims, wherein the BMP
is recombinantly produced in a yeast or in a bacterium.
is recombinantly produced in a yeast or in a bacterium.
25. The composition according to any of the preceding claims, wherein the BMP
is recombinantly produced in bacterium Escherichia coli.
is recombinantly produced in bacterium Escherichia coli.
26. The composition according claim 20, wherein the BMP is recombinantly produced in a cell capable of protein glycosylation.
27. The composition according to claim 26, wherein the BMP is produced in a cell selected from the group consisting of mammalian, bird, yeast, and insect.
28. The composition according to claim 24, wherein the BMP is produced in a bacterium selected from the group E. coli, Bacillus subtilis, and Streptomyces spp.
29. The composition according to any of the preceding claims, wherein BMP, in relation to the amount of collagen comprises a proportion of about 0.005 to about 5 weight percent, preferably from about 0.01 to about 4 weight percent.
30. The composition according to claim 29, wherein the BMP comprises a proportion of about 0.05 to about 2 weight percent, preferably from about 0.1 to about 5 weight percent, preferably from about 0.5 to about 3 weight percent.
31. The composition according to any of the preceding claims, further additionally comprising at least one scaffold material having osteo-conductive properties.
32. The composition according to claim 31, wherein the scaffold material comprises collagen, preferably type I collagen, preferably human type I collagen.
33. The composition according to claim 32, wherein the scaffold material comprises at least one substance selected from the group of tricalcium phosphate, ceramic materials, biologically compatible metals, and biologically compatible polymers.
34. The composition according to claim 33, wherein the scaffold material is tricalcium phosphate or a biphasic material comprising tricalcium phosphate.
35. The composition according to any of the preceding claims, further comprising at least one additional active substance, preferably at least one cytostatic and/or at least one antibiotic.
36. The composition according to any of the preceding claims, further comprising at least one additional component having an activity selected from the group of at least one recruiting factor, at least one adhesion factor, at least one growth factor and at least one maturation factor for osteogenesis or chondrogenesis.
37. The composition according to any of the preceding claims, wherein the human collagen is recombinantly produced.
38. The composition according to any of the preceding claims, further comprising a porous form with pores, preferably interconnecting pores, preferably with diameters in the range of about 100 µm to about 300 µm wherein the composition has a spongy consistency.
39. The composition according to any of the preceding claims that is substantially bioresorbable or is essentially completely bioresorbable.
40. The composition according to any of the preceding claims, provided as a gel, or a paste.
41. The composition according to any of the preceding claims, comprising a substantially form-stable body.
42. A composition for treating bone and/or cartilage defects comprising an aseptically prepared admixture of a recombinant human collagen and a recombinant human bone morphogenesis protein (BMP) wherein the collagen and the BMP are sterile and are aseptically mixed and co-lyophilized or co-granulated.
43. The composition according to claim 42, wherein the BMP has an amino acid sequence that is at least about 70%, about 80%, about 85%, about 90%, or at least about 95%
identical to an amino acid sequence of a BMP of human origin.
identical to an amino acid sequence of a BMP of human origin.
44. The composition according to either of claim 42 and 43, wherein the BMP is produced in a bacterium.
45. The composition according to any of claims 42-44, wherein the BMP is produced in E.
coli.
coli.
46. The composition according claim 42, wherein the BMP is recombinantly produced in a cell capable of protein glycosylation.
47. The composition according to claim 46, wherein the BMP is produced in a cell selected from the group consisting of a mammalian, bird, yeast, and insect cell.
48. The composition according to any of claims 42-47, wherein BMP, in relation to the amount of collagen comprises a proportion of about 0.005 to about 5 weight percent, preferably from about 0.01 to about 4 weight percent.
49. The composition according to claim 48, wherein the BMP comprises a proportion of about 0.05 to about 2 weight percent, preferably from about 0.1 to about 5 weight percent, preferably from about 0.5 to about 3 weight percent.
50. A method for manufacturing the composition according to any of claims 1-49, the method comprising: mixing components comprising at least one collagen, preferably of animal origin and preferably having at least one osteo-inductive or chondro-inductive activity, with at least one differentiation or growth factor having osteo-stimulative and/or chondro-stimulative activity, and co-lyophilizing the components to obtain an at least partly form-stable, spongy body.
51. The method according to claim 50, wherein the collagen is of non-human origin, the method further comprises prior to mixing, contacting the collagen with a peptidase or protease, preferably trypsin.
52. The method according to claim 42 or 43, further comprising prior to mixing, concentrating the differentiation or growth factor, preferably in at least one separation step.
53. The method according to any of claims 50 to 52, the method further comprising prior to mixing, adding at least one scaffold material, wherein the scaffold material has osteo-conductive properties and is selected from the group of ceramic materials, biologically compatible metals, biologically compatible polymers and extracts of native bone, preferably DBM, and mixing, preferably coating, with collagen; and mixing with at least one collagen, preferably of animal origin with an osteo-inductive or a chondro-inductive, active substance and/or at least one additive of at least one differentiation or growth factor with osteo-stiinulative and/or chondro-stimulative effect; and colyophilizing the components to obtain an at least partly form stable, spongy body.
54. The method according to one of the claims 50 to 53, performed under aseptic conditions.
55. A use of at least one differentiation and/or growth factor with osteo-stimulative and/or chondro-stimulative effect, the use comprising mixing aseptically a sterile solution of the growth factor with a sterile solution of at least one collagen, preferably of animal origin and preferably having at least one osteo-inductive or chondro-inductive, active substance; and, co-lyophilizing aseptically the resulting mixture in a container for single use as an implant in surgery.
56. A use of at least one human bone morphogenesis protein (BMP) for treating a bone and/or cartilage defect during a surgical procedure, the use comprising adding the BMP
to at least one human collagen and at least one scaffold material to obtain an admixture, and providing the admixture as an aseptic device for treating a bone and/or cartilage defect during a surgical procedure.
to at least one human collagen and at least one scaffold material to obtain an admixture, and providing the admixture as an aseptic device for treating a bone and/or cartilage defect during a surgical procedure.
57. The use according to claim 56, wherein the device is provided as a surgery-ready unit dose.
58. The use according to claim 57, wherein the composition is a lyophil, a gel or a paste.
59. A method for formulating a composition for treating bone and cartilage defects, the method comprising: mixing aseptically a solution of a recombinant human collagen with a solution of an amino acid sequence of a recombinant human bone morphogenesis protein; and granulating or lyophilizing aseptically the admixture to a gel, paste, or a lyophil having an at least partly form-stable shape and a spongy consistency.
60. The method according to claim 59, wherein the solution of the collagen and the solution of the bone morphogenesis protein are sterile or have a reduced microbial content.
61. The method according to claim 59 or 60, further comprising, prior to the mixing, concentrating the collagen, preferably in at least one separation step, and wherein the collagen is treated with acid or filter sterilized prior to or after concentrating.
62. The method according to any of claims 59 to 61, further comprising prior to mixing, providing at least one scaffold material selected from the group of ceramic materials, biologically compatible metals, biologically compatible polymers and extracts of native bone, preferably DBM; mixing or preferably coating the scaffold material with the collagen; and colyophilizing or co-granulating the admixture to obtain an at least partly form-stable, spongy body.
63. The method according to claim 62, wherein prior to mixing, the collagen is sterilized by filter sterilizing or acidifying, the scaffold material is irradiated, and mixing is performed under aseptic conditions.
64. A kit for treating a bone and/or cartilage defect during a surgical procedure comprising an aseptically prepared admixture in the form of a lyophil, a gel or a paste, the admixture comprising a recombinant human bone morphogenesis protein (BMP) and a recombinant human collagen, in a container.
65. The kit according to claim 64, wherein the admixture is present in a surgery-ready unit dose.
66. The kit according to claim 64, further comprising instructions for direct use of the aseptic admixture as an implant without additional manipulation.
67. An aseptic device for surgical implantation for treating bone and/or cartilage defects comprising an admixture of a recombinantly produced human differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect and at least one scaffold material, wherein the factor is at least about 70% identical in amino acid sequence to a human growth factor, wherein the device is provided as a single component for surgical implantation.
68. The device according to claim 67, wherein the growth factor is glycosylated.
69. The device according to claim 67, wherein the growth factor is non-glycosylated.
70. The device according to claim 68, wherein the growth factor is recombinantly produced in a cell of a yeast, a mammal or a bird.
71. The device according to claim 69, wherein the growth factor is recombinantly produced in a bacterium.
72. The device according to claim 69, wherein the growth factor is recombinantly produced in E. coli.
73. The device according to any of the preceding claims, wherein the growth factor comprises a member of the TGF (Transforming Growth Factor) family.
74. The device according to claim 73, wherein the growth factor is at least one selected from the group of Bone Morphogenetic Proteins (BMP) comprising BMP-2, BMP-7, BMP-9, BMP-16; Vascular Endothelial Growth Factor (VEGF); Transforming Growth Factor .beta.
(TGF.beta.), Platelet Derived Growth Factor (PDGF), Insulin-like Growth Factor (IGF) and p15.
(TGF.beta.), Platelet Derived Growth Factor (PDGF), Insulin-like Growth Factor (IGF) and p15.
75. The device according to claim 73, wherein the growth factor is a human BMP-2 or a human BMP-7 and is recombinantly produced and nature-identical.
76. The device according to any of the preceding claims further comprising collagen, wherein the ratio of the differentiation or growth factor in relation to the amount of collagen comprises a share of about 0.005 to about 5 percent by weight, preferably from about 0.01 to about 4 percent by weight.
77. The device according to claim 76, wherein the growth factor comprises a share of about 0.05 to about 2 percent by weight, preferably from about 0.1 to about 5 percent by weight, preferably from about 0.5 to about 3 percent by weight.
78. The device according to any claims 67-77, further comprising at least one scaffold material, preferably a scaffold material having an osteo-conductive activity.
79. The device according to claim 78, wherein the scaffold is collagen having an amino acid sequence substantially identical to a human collagen.
80. The device according to claim 79, wherein the collagen is recombinantly produced.
81. The device according to claim 77, wherein the scaffold material is at least one selected from the group of ceramics, biologically compatible metals and biologically compatible polymers.
82. The device according to any of claims 67-81, further comprising at least one additional active substance selected from the group of at least one cytostatic agent and/or at least one antibiotic.
83. The device according to any of any of claims 67-82, further comprising at least one component selected from the group of: a recruiting factor, an adhesion factor, a growth factor and a maturation factor for osteogenesis or chondrogenesis.
84. The device according to any of any of claims 67-83, wherein the co-lyophil or co-granulate is a spongy form-stable body that comprises pores.
85. The device according to claim 84 wherein the pores have a diameter in the range of about 100 µm to about 300 µm, and wherein the admixture has a consistency and stable form of a surgical sponge.
86. The device according to any of any of claims 67-85, wherein the admixture is at least partially bio-resorbable, preferably completely bio-resorbable.
87. The device according to any of claims 67-86, wherein the admixture is aseptically prepared from aseptic or sterile components.
88. The device according to any of claims 67-87, further comprising a closed container.
89. The device according to claim 88, wherein the admixture is aseptically lyophilized in the container.
90. The device according to claim 89, wherein the container is aseptically covered with a material capable of unidirectional passage of solvent molecules during lyophilization.
91. The device according to claim 78 wherein the scaffold material comprises human recombinant collagen.
92. The device according to claim 91, wherein the collagen is selected from at least one of a type I and a type III collagen.
93. The device according to claim 78, wherein the scaffold material comprises a mineral.
94. The device according to claim 93, wherein the mineral is selected from the group consisting of: tricalcium phosphate, ceramic materials, biologically compatible metals, and biologically compatible polymers.
95. The device according to claim 91, wherein the collagen is cross-linked.
96. The device according to claim 91, wherein the collagen is covalently linked to the growth factor with any of a reagent commonly known to be used to cross-link proteins.
97. The device according to any of the claims 67-96, wherein the collagen is covalently linked to the growth factor, and the device is lyophilized aseptically and used as an implant in a subject for treatment of a bone and/or a cartilage defect.
98. The device according to claim 97, wherein following implanting into the subject, the device is subsequently metabolized releasing the covalently bound growth factor slowly, compared to release in a burst at an early time point following implant into the subject of an otherwise identically constituted and non-covalently bound growth factor.
99. The device according to claim 97 wherein the covalently linked device is obtained by contacting the collagen and osteo- and/or chondro-stimulating factors with a bidentate, low molecular cross-linking reagent selected from the group of commonly used in protein and peptide chemistry reagents: 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), succinic anhydride, a di-isocyanates, an activated and properly protected amino acids, a double activated polyethylene-glycol, and an activated carbon hydrate, to obtain quantitative binding of the reagent to the collagen
100. The device according to any of claims 97-99, wherein following quantitative binding of the reagent to collagen, the device is further prepared by the steps of:
removing excess reagent by dialyzing to obtain a modified collagen that retains protein features having a biological activity selected from the group of osteo-inductive, chondro-inductive, osteo-conductive and chrondo-conductive; mixing the modified collagen with the growth factor/s for a time appropriate for cross-linking; and lyophilyzing, wherein the steps are performed aseptically.
removing excess reagent by dialyzing to obtain a modified collagen that retains protein features having a biological activity selected from the group of osteo-inductive, chondro-inductive, osteo-conductive and chrondo-conductive; mixing the modified collagen with the growth factor/s for a time appropriate for cross-linking; and lyophilyzing, wherein the steps are performed aseptically.
101. The device according to any of claims 97-100 comprising materials that are aseptic, wherein the device has a reduced microbial content.
102. The device according to claim 91, further comprising at least one additional component capable of retarding release of the growth factor from the scaffold, wherein the component is preferably a plasma protein such as fibrin.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99314607P | 2007-09-10 | 2007-09-10 | |
US60/993,146 | 2007-09-10 | ||
PCT/EP2008/001604 WO2008107122A2 (en) | 2007-03-08 | 2008-02-29 | Composition for the treatment of bone and/or cartilage defects |
EPPCT/EP08/001604 | 2008-02-29 | ||
PCT/IB2008/002367 WO2009034452A2 (en) | 2007-09-10 | 2008-09-05 | Compound and device for treating bone and/or cartilage defects |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2686439A1 true CA2686439A1 (en) | 2009-03-19 |
Family
ID=40452623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002686439A Abandoned CA2686439A1 (en) | 2007-09-10 | 2008-09-05 | Compound and device for treating bone and/or cartilage defects |
Country Status (7)
Country | Link |
---|---|
JP (1) | JP2010538691A (en) |
KR (1) | KR20100052430A (en) |
CN (1) | CN101631562A (en) |
AU (1) | AU2008299484A1 (en) |
CA (1) | CA2686439A1 (en) |
IL (1) | IL200820A0 (en) |
WO (1) | WO2009034452A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101400667B1 (en) * | 2011-04-22 | 2014-05-30 | 주식회사 나이벡 | Surface Activated Collagen Membrane by Peptide |
JP2014156410A (en) * | 2013-02-14 | 2014-08-28 | Nagoya Univ | Histogenetic composition, and use thereof |
GB201402648D0 (en) * | 2014-02-14 | 2014-04-02 | Athlone Inst Of Technology | Composition |
CN105012995B (en) * | 2015-06-04 | 2018-03-09 | 武汉维斯第医用科技股份有限公司 | A kind of collagen protein sponge of the knitting medicine containing rush and preparation method thereof |
KR101694392B1 (en) * | 2016-06-02 | 2017-01-10 | 단국대학교 천안캠퍼스 산학협력단 | Electromechanical cartilage reshaping apparatus based on current control for controling pain |
BR112021006752A2 (en) * | 2018-10-12 | 2021-07-13 | Theradaptive, Inc. | polypeptides including a tricalcium beta phosphate binding sequence and uses thereof |
CN109289088B (en) * | 2018-10-26 | 2021-04-27 | 福州大学 | Type I/III collagen composite bracket loaded with caulis spatholobi |
EP3695856A1 (en) * | 2019-02-13 | 2020-08-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Biomaterials comprising a scaffold containing a mineral compound, and uses thereof as bone substitutes |
GB201917246D0 (en) * | 2019-11-27 | 2020-01-08 | Royal College Surgeons Ireland | A collagen scaffold |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5290763A (en) * | 1991-04-22 | 1994-03-01 | Intermedics Orthopedics/Denver, Inc. | Osteoinductive protein mixtures and purification processes |
US20020114795A1 (en) * | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
US7375077B2 (en) * | 2003-09-19 | 2008-05-20 | The Board Of Trustees Of The University Of Illinois | In vivo synthesis of connective tissues |
DE102004036881A1 (en) * | 2004-07-22 | 2006-02-16 | Ossacur Ag | Bioresorbable material for filling bone defects |
-
2008
- 2008-09-05 AU AU2008299484A patent/AU2008299484A1/en not_active Abandoned
- 2008-09-05 CA CA002686439A patent/CA2686439A1/en not_active Abandoned
- 2008-09-05 CN CN200880007545A patent/CN101631562A/en active Pending
- 2008-09-05 KR KR1020097021182A patent/KR20100052430A/en not_active Application Discontinuation
- 2008-09-05 WO PCT/IB2008/002367 patent/WO2009034452A2/en active Application Filing
- 2008-09-05 JP JP2010523606A patent/JP2010538691A/en active Pending
-
2009
- 2009-09-08 IL IL200820A patent/IL200820A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008299484A2 (en) | 2009-10-08 |
WO2009034452A3 (en) | 2009-06-04 |
IL200820A0 (en) | 2010-05-17 |
WO2009034452A4 (en) | 2009-08-20 |
WO2009034452A2 (en) | 2009-03-19 |
CN101631562A (en) | 2010-01-20 |
AU2008299484A1 (en) | 2009-03-19 |
JP2010538691A (en) | 2010-12-16 |
KR20100052430A (en) | 2010-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8586070B2 (en) | Composition and device for treating bone and/or cartilage defects | |
CA2686439A1 (en) | Compound and device for treating bone and/or cartilage defects | |
Caballé‐Serrano et al. | Collagen barrier membranes adsorb growth factors liberated from autogenous bone chips | |
Damien et al. | Bone graft and bone graft substitutes: a review of current technology and applications | |
Dai et al. | Repairing of goat tibial bone defects with BMP-2 gene–modified tissue-engineered bone | |
Bostrom et al. | Use of bone morphogenetic protein-2 in the rabbit ulnar nonunion model | |
Kroese-Deutman et al. | Bone inductive properties of rhBMP-2 loaded porous calcium phosphate cement implants inserted at an ectopic site in rabbits | |
Boden et al. | The Use of an Osteoinductive Growth Factor for Lumbar Spinal Fusion: Part II: Study of Dose, Carrier, and Species | |
Geiger et al. | VEGF producing bone marrow stromal cells (BMSC) enhance vascularization and resorption of a natural coral bone substitute | |
Hotz et al. | Bone substitute with osteoinductive biomaterials—current and future clinical applications | |
Kasten et al. | Comparison of platelet-rich plasma and VEGF-transfected mesenchymal stem cells on vascularization and bone formation in a critical-size bone defect | |
Kim et al. | Promising efficacy of Escherichia coli recombinant human bone morphogenetic protein-2 in collagen sponge for ectopic and orthotopic bone formation and comparison with mammalian cell recombinant human bone morphogenetic protein-2 | |
Schützenberger et al. | The optimal carrier for BMP-2: a comparison of collagen versus fibrin matrix | |
Southwood et al. | Delivery of growth factors using gene therapy to enhance bone healing | |
US8524253B2 (en) | Bone regeneration device | |
US20050136042A1 (en) | Methods and compositions for tissue repair | |
Jabbari | Osteogenic peptides in bone regeneration | |
JP2010512974A (en) | Flowable carrier composition and method of use | |
Oppenheimer et al. | Current and emerging basic science concepts in bone biology: implications in craniofacial surgery | |
Herberg et al. | Mesenchymal stem cell expression of SDF‐1β synergizes with BMP‐2 to augment cell‐mediated healing of critical‐sized mouse calvarial defects | |
Wei et al. | Augmentation of fracture healing by hydroxyapatite/collagen paste and bone morphogenetic protein‐2 evaluated using a rat femur osteotomy model | |
Viljanen et al. | Xenogeneic moose (Alces alces) bone morphogenetic protein (mBMP)-induced repair of critical-size skull defects in sheep | |
WH Lo et al. | Current patents on osteoinductive molecules for bone tissue engineering | |
US7728116B2 (en) | Method of preparing an osteogenic protein fraction | |
Zhang et al. | The enhancement of osteogenic capacity in a synthetic BMP-2 derived peptide coated mineralized collagen composite in the treatment of the mandibular defects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20140905 |